U.S. patent application number 17/653904 was filed with the patent office on 2022-07-07 for substituted heterocycles as cyclic trex1 inhibitors.
This patent application is currently assigned to VENENUM BIODESIGN, LLC. The applicant listed for this patent is VENENUM BIODESIGN, LLC. Invention is credited to Venugopalareddy BOMMIREDDY VENKATA, Chia-Yu HUANG, Jeffrey J. LETOURNEAU, Kiruthika SELVARANGAN ELAMPARUTHI.
Application Number | 20220213111 17/653904 |
Document ID | / |
Family ID | |
Filed Date | 2022-07-07 |
United States Patent
Application |
20220213111 |
Kind Code |
A1 |
LETOURNEAU; Jeffrey J. ; et
al. |
July 7, 2022 |
SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS
Abstract
The present invention provides compounds of Formula I:
##STR00001## wherein {circle around (A)}, X, R.sub.1, R.sub.2,
R.sub.3 and R.sub.4 are as defined herein, or a stereoisomer,
tautomer, pharmaceutically acceptable salt, prodrug ester or
solvate form thereof, wherein all of the variables are as defined
herein. These compounds are effective at modulating the TREX1
protein and thus can be used as medicaments for treating or
preventing disorders affected by the inhibition of TREX1.
Inventors: |
LETOURNEAU; Jeffrey J.;
(East Windsor, NJ) ; SELVARANGAN ELAMPARUTHI;
Kiruthika; (Princeton Junction, NJ) ; HUANG;
Chia-Yu; (West Windsor, NJ) ; BOMMIREDDY VENKATA;
Venugopalareddy; (Princeton Junction, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
VENENUM BIODESIGN, LLC |
Hamilton |
NJ |
US |
|
|
Assignee: |
VENENUM BIODESIGN, LLC
Hamilton
NJ
|
Appl. No.: |
17/653904 |
Filed: |
March 8, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16829655 |
Mar 25, 2020 |
11306098 |
|
|
17653904 |
|
|
|
|
62830626 |
Apr 8, 2019 |
|
|
|
International
Class: |
C07D 487/04 20060101
C07D487/04; A61P 35/00 20060101 A61P035/00 |
Claims
1.-9. (canceled)
10. A method of treating a disorder, disease, syndrome, or
condition, wherein said disease, syndrome, or condition is affected
by the inhibition of TREX1, comprising administering to a subject
in need thereof a therapeutically effective amount of the compound,
stereoisomer, tautomer, pharmaceutically acceptable salt, or
solvate of a compound of Formula I: ##STR00088## or a
pharmaceutically acceptable salt, solvate, stereoisomer, or
tautomer thereof, wherein: ##STR00089## X is --C.sub.1-C.sub.6
alkylene-NR.sub.SC(O)--, --C.sub.1-C.sub.6
alkylene-NR.sub.5S(O).sub.2--, --C(O)NR.sub.5--,
--C(O)NR.sub.5S(O).sub.2--, or a 5-membered heteroarylene, wherein
the 5-membered heteroarylene contains at least 1 nitrogen
heteroatom; R.sub.1 is C.sub.1-C.sub.6 alkylene-NR.sub.5R.sub.6 or
NR.sub.5R.sub.6; R.sub.2 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylene-O-C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6 alkylene-O-5- to
10-membered heteroaryl, C.sub.1-C.sub.6
alkylene-S--C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6 alkylene-S-5- to
10-membered heteroaryl, C.sub.1-C.sub.6
alkylene-S(O)--C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6
alkylene-S(O)-5- to 10-membered heteroaryl, C.sub.1-C.sub.6
alkylene-S(O).sub.2-C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6
alkylene-S(O).sub.2-- 5- to 10-membered heteroaryl, C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, or C.sub.1-C.sub.6 alkylene-5- to
10-membered heteroaryl, wherein any C.sub.6-C.sub.10 aryl or 5- to
10-membered heteroaryl is optionally and independently substituted
with 1 or more substituents independently selected from the group
consisting of halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4
haloalkyl; R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylene-C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6 alkylene-5- to
10-membered heteroaryl, or C.sub.6-C.sub.10 aryl, wherein any
C.sub.3-C.sub.6 cycloalkyl, C.sub.6-C.sub.10 aryl, or 5- to
10-membered heteroaryl is optionally and independently substituted
with 1 or more substituents independently selected from the group
consisting of halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.6
haloalkyl; R.sub.4 is C.sub.1-C.sub.6 alkyl, wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
CN, C(O)NR.sub.8R.sub.9, C(O)NR.sub.8S(O).sub.2R.sub.9,
C(O)NR.sub.8S(O).sub.2NR.sub.28R.sub.29, C(O)OH, NR.sub.8R.sub.9,
NR.sub.28C(O)NR.sub.8R.sub.9,
NR.sub.28C(O)NR.sub.8S(O).sub.2R.sub.9, NR.sub.8S(O).sub.2R.sub.9,
OH, ONR.sub.8R.sub.9, SR.sub.9, S(O)R.sub.9, S(O).sub.2R.sub.9,
S(O).sub.2NR.sub.8R.sub.9, S(O).sub.2OH, C.sub.6-C.sub.10 aryl, and
a 5- to 10-membered heteroaryl,wherein the 5- to 10-membered
heteroaryl contains at least 1 nitrogen heteroatom, and further
wherein any C.sub.6-C.sub.10 aryl or 5- to 10-membered heteroaryl
is optionally and independently substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OH,
.dbd.O, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4 haloalkyl;
each R.sub.5 is independently H, C.sub.1-C.sub.6 alkyl, or
C.sub.1-C.sub.6 haloalkyl; each R.sub.6 is independently H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, or C(O)R.sub.7;
each R.sub.7 is independently C.sub.1-C.sub.6 alkyl or
OC.sub.1-C.sub.6 alkyl; each R.sub.8 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl,
C(O)C.sub.1-C.sub.4 alkyl, OC.sub.1-C.sub.4 alkyl, or
OC.sub.1-C.sub.4 haloalkyl; each R.sub.9 is independently H,
C.sub.1-C.sub.4 alkyl, OH, OC.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.6
cycloalkyl, or C.sub.6-C.sub.10 aryl, wherein each C.sub.1-C.sub.4
alkyl, OC.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.6 cycloalkyl, and
C.sub.6-C.sub.10 aryl is optionally and independently substituted
with 1 or more substituents independently selected from the group
consisting of halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, OH, .dbd.O, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4
haloalkyl; each R.sub.28 is independently H, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 haloalkyl, OC.sub.1-C.sub.4 alkyl, or
OC.sub.1-C.sub.4 haloalkyl; and each R.sub.29 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OC.sub.1-C.sub.4
alkyl, or OC.sub.1-C.sub.4 haloalkyl.
11. The method of claim 10, wherein said disorder, disease,
syndrome, or condition is cancer.
12. A method of treating a disorder, disease, syndrome, or
condition selected from the group consisting of viral infection,
melanoma, colon cancer, breast cancer, prostate cancer, lung
cancer, bladder cancer and fibrosarcoma, comprising administering
to a subject in need thereof a therapeutically effective amount of
the composition of claim 8.
13. A method of treating a disorder, disease, syndrome, or
condition selected from the group consisting of viral infection,
melanoma, colon cancer, breast cancer, prostate cancer, lung
cancer, bladder cancer and fibrosarcoma, comprising administering
to a subject in need thereof a therapeutically effective amount of
the composition of claim 9.
14. (canceled)
15. (canceled)
16. The method of claim 10, wherein: X is --C.sub.1-C.sub.6
alkylene-NR.sub.5C(O)--, --C(O)NR.sub.5--,
--C(O)NR.sub.5S(O).sub.2--, or a 5-membered heteroarylene, wherein
the 5-membered heteroarylene contains at least 1 nitrogen
heteroatom; R.sub.2 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylene-O--C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6
alkylene-S(O)--C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6 alkylene-
S(O)--C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6
alkylene-S(O).sub.2--C.sub.6-C.sub.10 aryl, or C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl
is optionally and independently substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OH,
OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4 haloalkyl; R.sub.3 is
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10
aryl, C.sub.1-C.sub.6 alkylene-5- to 10-membered heteroaryl, or
C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl or the 5-
to 10-membered heteroaryl is optionally and independently
substituted with 1 or more substituents independently selected from
the group consisting of halo, CN, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and
OC.sub.1-C.sub.6 haloalkyl; R.sub.4 is C.sub.1-C.sub.6 alkyl,
wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with 1
or more substituents independently selected from the group
consisting of CN, C(O)NR.sub.8R.sub.9, C(O)OH, OH, C.sub.6-C.sub.10
aryl, and 5-membered heteroaryl, wherein the 5-membered heteroaryl
contains at least 1 nitrogen heteroatom, and further wherein any
C.sub.6-C.sub.10 aryl or 5-membered heteroaryl is optionally and
independently substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 haloalkyl, OH, .dbd.O, OC.sub.1-C.sub.4
alkyl, and OC.sub.1-C.sub.4 haloalkyl; each R.sub.8 is
independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl,
or OC.sub.1-C.sub.4 alkyl; and each R.sub.9 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, or
OC.sub.1-C.sub.4 alkyl.
17. The method of claim 10, wherein: X is --C.sub.1-C.sub.6
alkylene-NR.sub.5C(O)--, --C(O)NR.sub.5--, or a 5-membered
heteroarylene, wherein the 5-membered heteroarylene contains at
least 1 nitrogen heteroatom; R.sub.2 is C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylene-O-C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.6
alkylene-S-C.sub.6-C.sub.10 aryl, or C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl
is optionally and independently substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OH,
OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4 haloalkyl; R.sub.3 is
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10
aryl, C.sub.1-C.sub.6 alkylene-5-membered heteroaryl, or
C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl or
5-membered heteroaryl is optionally and independently substituted
with 1 or more substituents independently selected from the group
consisting of halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.6
haloalkyl; R.sub.4 is C.sub.1-C.sub.6 alkyl, wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
CN, C(O)NR.sub.8R.sub.9, C(O)OH, OH, C.sub.6-C.sub.10 aryl, and
5-membered heteroaryl, wherein the 5-membered heteroaryl contains
at least 1 nitrogen heteroatom, and further wherein any
C.sub.6-C.sub.10 aryl or 5-membered heteroaryl is optionally and
independently substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 haloalkyl, OH, .dbd.O, OC.sub.1-C.sub.4
alkyl, and OC.sub.1-C.sub.4 haloalkyl; each R.sub.8 is
independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl,
or OC.sub.1-C.sub.4 alkyl; and each R.sub.9 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, or
OC.sub.1-C.sub.4 alkyl.
18. The method of claim 17, wherein:: X is --C(O)NR.sub.5--;
R.sub.1 is NR.sub.5R.sub.6; R.sub.2 is C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, wherein the C.sub.6-C.sub.10 aryl
is optionally substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, OH, and OC.sub.1-C.sub.4 haloalkyl; R.sub.3 is
C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10 aryl, wherein the
C.sub.6-C.sub.10 aryl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, and OH;
R.sub.4 is C.sub.1-C.sub.6 alkyl, wherein the C.sub.1-C.sub.6 alkyl
is optionally substituted with 1 or more substituents independently
selected from the group consisting of C(O)OH, OH, C.sub.6-C.sub.10
aryl, and 5-membered heteroaryl, wherein the 5-membered heteroaryl
contains at least 1 nitrogen heteroatom, and further wherein any
C.sub.6-C.sub.10 aryl or 5-membered heteroaryl is optionally and
independently substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 haloalkyl, OH, .dbd.O, OC.sub.1-C.sub.4
alkyl, and OC.sub.1-C.sub.4 haloalkyl; each R.sub.5 is
independently H or CH.sub.3; and R.sub.6 is H or C.sub.1-C.sub.6
alkyl.
19. The method of claim 10, wherein: ##STR00090##
20. The method of claim 19, wherein: R.sub.4 is C.sub.1-C.sub.6
alkyl, wherein the C.sub.1-C.sub.6 alkyl is substituted with 1
substituent selected from the group consisting of C(O)OH and
5-membered heteroaryl, wherein the 5-membered heteroaryl contains
at least 1 nitrogen heteroatom, and further wherein the 5-membered
heteroaryl is optionally substituted with 1 or more substituents
independently selected from the group consisting of halo, CN,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OH, .dbd.O,
OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4 haloalkyl.
21. The method of claim 10, wherein: X is --C.sub.1-C.sub.6
alkylene-NR.sub.5C(O)-- or --C(O)NR.sub.5--; R.sub.2 is
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylene-O--C.sub.6-C.sub.10
aryl, or C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10 aryl, wherein
any C.sub.6-C.sub.10 aryl is optionally and independently
substituted with 1 or more substituents independently selected from
the group consisting of halo, CN, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and
OC.sub.1-C.sub.4 haloalkyl; R.sub.3 is C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10 aryl, or C.sub.6-C.sub.10
aryl, wherein any C.sub.6-C.sub.10 aryl is optionally and
independently substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and
OC.sub.1-C.sub.6 haloalkyl; R.sub.4 is C1-C6 alkyl, wherein the
C.sub.1-C.sub.6 alkyl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
CN, C(O)NR.sub.8R.sub.9, C(O)OH, OH, and C.sub.6-C.sub.10 aryl,
wherein any C.sub.6-C.sub.10 aryl is optionally and independently
substituted with 1 or more substituents independently selected from
the group consisting of halo, CN, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and
OC.sub.1-C.sub.4 haloalkyl; each R.sub.8 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, or
OC.sub.1-C.sub.4 alkyl; and each R.sub.9 is independently H,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, or
OC.sub.1-C.sub.4 alkyl.
22. The method of claim 10, wherein: X is --C.sub.1-C.sub.6
alkylene-NR.sub.5C(O)-- or --C(O)NR.sub.5--; R.sub.2 is
C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10
aryl, wherein the C.sub.6-C.sub.10 aryl is optionally substituted
with 1 or more substituents independently selected from the group
consisting of halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4
haloalkyl; R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, or C.sub.6-C.sub.10 aryl, wherein
any C.sub.6-C.sub.10 aryl is optionally and independently
substituted with 1 or more substituents independently selected from
the group consisting of halo, CN, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 haloalkyl, OH, OC.sub.1-C.sub.4 alkyl, and
OC.sub.1-C.sub.6 haloalkyl; R.sub.4 is C.sub.1-C.sub.6 alkyl,
wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with 1
or more substituents independently selected from the group
consisting of CN, C(O)NR.sub.8R.sub.9, C(O)OH, OH, and
C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl is
optionally and independently substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, OH,
OC.sub.1-C.sub.4 alkyl, and OC.sub.1-C.sub.4 haloalkyl; each
R.sub.8 is independently H, C.sub.1-C.sub.4 alkyl, or
C.sub.1-C.sub.4 haloalkyl; and each R.sub.9 is independently H,
C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 haloalkyl.
23. The method of claim 10, wherein: X is --C(O)NR.sub.5--; R.sub.1
is NR.sub.5R.sub.6; R.sub.2 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 alkylene-C.sub.6-C.sub.10 aryl, wherein the
C.sub.6-C.sub.10 aryl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, and OH;
R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkylene-C.sub.6-C.sub.10 aryl, or C.sub.6-C.sub.10 aryl, wherein
the C.sub.6-C.sub.10 aryl is optionally substituted with 1 or more
substituents independently selected from the group consisting of
halo, CN, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, and OH;
R.sub.4 is C.sub.1-C.sub.6 alkyl, wherein the C.sub.1-C.sub.6 alkyl
is optionally substituted with 1 or more substituents independently
selected from the group consisting of C(O)OH, OH, and
C.sub.6-C.sub.10 aryl, wherein any C.sub.6-C.sub.10 aryl is
optionally substituted with 1 or more substituents independently
selected from the group consisting of halo, CN, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 haloalkyl, and OH; each R.sub.5 is
independently H or C.sub.1-C.sub.6 alkyl; R.sub.6 is H,
C.sub.1-C.sub.6 alkyl, or C(O)R.sub.7;. and R.sub.7 is
C.sub.1-C.sub.6 alkyl or OC.sub.1-C.sub.6 alkyl.
24. The method of claim 20, wherein the compound is selected from
the group consisting of: ##STR00091##
25. The method of claim 10, wherein the compound is selected from
the group consisting of: ##STR00092## ##STR00093## ##STR00094##
##STR00095## ##STR00096## ##STR00097## ##STR00098## ##STR00099##
Description
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. .sctn.
119 (e) to U.S. Provisional Application No. 62/830,626, filed on
Apr. 8, 2019, the contents of which are incorporated by reference
herein in its entirety.
FIELD OF THE INVENTION
[0002] The present invention provides novel cyclic compounds, and
analogues thereof, which are three prime repair exonuclease 1
(TREX1) inhibitors and are useful in preventing or treating
disorders associated with TREX1. This invention also relates to
pharmaceutical compositions containing these compounds and methods
of using the same.
BACKGROUND OF THE INVENTION
[0003] Three-prime repair exonuclease 1 (gene name TREX-1), also
called Deoxyribonuclease III or DNase III, is an enzyme that
degrades deoxyribonucleic acid by cleaving the 3' terminal base of
a DNA polymer. TREX1 can digest single-stranded and double-stranded
DNA containing a mismatched 3' overhang. TREX1 is an endoplasmic
reticulum-associated cytosolic protein and can also be found in the
nucleus.
[0004] TREX1 functions to prevent cell-intrinsic initiation of
autoimmunity by degrading cytosolic self DNA from endogenous
retroelements (Stetson, D. B et al. (2008) Cell. 134(4). 587-598).
TREX 1 prevents chronic ATM-dependent checkpoint activation by
processing ssDNA polynucleotide species arising from the processing
of aberrant DNA replication intermediates (Yang Y. G. et. al.
(2007) Cell 131(5), 873-86). Cytosolic DNA fragments and
retroelements are sensed by pattern recognition receptors, such as
cyclic GMP-AMP synthase (gene name cGAS). When cGAS binds DNA its
enzyme activity is greatly enhanced and it produces cyclic GMP-AMP
which serves as a secondary messenger that binds to and activates
Stimulator of Interferon Genes (STING) and thereby initiating a
type 1 interferon immune response (Wu J. et al., (2012) Science.
339(6121), 826-30; Sun L. et al., (2012). Science. 339(6121). TREX1
DNA degrading activity can attenuate such responses as a check to
prevent excessive type 1 interferon responses.
[0005] Defects in TREX1 have numerous biological consequences.
Defects in TREX1 function are associated with type 1 interferon
driven systemic inflammatory and autoimmune conditions. These
include Familial Chilblain Lupus, Aicardi-Goutie'res syndrome
(AGS), Retinal Vasculopathy and Cerebral leukodystrophy (RVCL)
(Ablasser, A. et al. (2014) J. Immun. 192, 5993-5997). Similar to
activating mutations of STING (Jeremiah, N. et al. (2014) JCI,
124(12), 5516-5520), inactivating mutations in TREX1 (Yan, N. et
al. (2017) J. Interfer. Cyt. Res. 2017 37(5), 198-206) are
associated with type 1 interferon-driven systemic inflammatory and
autoimmune conditions. It follows then that TREX1 inhibitors should
have the same therapeutic consequence as STING agonists in the
context of cancer immunotherapy. TREX1 inhibitors can be used in
combinatorial strategies to maximizing the immunogenicity of
radiation therapy (Vanpouille-Box (2017) Nature Commun. 8, 81658).
Inactivating mutations in TREX1 confers resistance to RNA viruses,
including HIV, VSV, influenza, West Nile and Sendai viruses.
Therefore, TREX1 inhibition could be used in antiviral therapy as
well.
[0006] The potential therapeutic benefits of enhancing both innate
and adaptive immunity make TREX1 an attractive therapeutic target
that demonstrates impressive activity by itself and can also be
combined with other immunotherapies.
SUMMARY OF THE INVENTION
[0007] It has been found that cyclic compounds in accordance with
the present invention are effective at inhibiting TREX1 in
assays.Accordingly, the present invention provides novel cyclic
analogues which are TREX1 inhibitors and are useful as selective
immunotherapies, including stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrug esters
thereof.
[0008] The present invention also provides processes and
intermediates for making the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrug esters thereof.
[0009] The present invention also provides pharmaceutical
compositions comprising a pharmaceutically acceptable carrier and
at least one of the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrug esters thereof.
[0010] The present invention also provides a method for the
treatment or prophylaxis of disorders, diseases, syndromes, or
conditions affected by the inhibition of TREX1 comprising
administering to a patient in need of such treatment or prophylaxis
a therapeutically effective amount of at least one of the compounds
of the present invention or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrug esters
thereof.
[0011] The present invention also provides the compounds of the
present invention or stereoisomers, tautomers, pharmaceutically
acceptable salts, solvates, or prodrug esters thereof, for use in
therapy.
[0012] The present invention also provides the use of the compounds
of the present invention or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrug esters
thereof, for the manufacture of a medicament for the treatment or
prophylaxis of a disorder, disease, syndrome, or condition affected
by the inhibition of TREX1.
[0013] Other features and advantages of the invention will be
apparent from the following detailed description and claims.
DETAILED DESCRIPTION
[0014] In one embodiment, the present invention provides cyclic
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, of Formula I having the structure:
##STR00002##
wherein:
[0015] A is a 6 to 7 -membered monocyclic heterocyclyl or a 8- to
12-membered bicyclic heterocyclyl, wherein the bicyclic
heterocyclyl contains at least two N atoms;
[0016] X is independently selected from --C(.dbd.O)--NR.sub.5--;
--C(.dbd.O)--NR.sub.5--S(.dbd.O).sub.2--; --C.sub.1-C.sub.6
alkyl-NR.sub.5--S(.dbd.O).sub.2--; --C.sub.1-C.sub.6
alkyl-NR.sub.5--C(.dbd.O)--; and a 5-membered nitrogen containing
heteroaryl;
[0017] R.sub.1 is independently selected from --C.sub.1-C.sub.6
alkyl-NR.sub.5R.sub.6 and --NR.sub.5R.sub.6;
[0018] R.sub.2 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryloxy-C.sub.1-C.sub.6-alkyl,
C.sub.6-C.sub.10 aryl S--C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10
aryl-S(.dbd.O)--C.sub.1-C.sub.6-alkyl, C.sub.6-C.sub.10
aryl-S(.dbd.O).sub.2-C.sub.1-C.sub.6-alkyl, C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, a 5- to 10-membered
heteroaryl-oxy-C.sub.1-C.sub.6-alkyl, a 5- to 10-membered
heteroaryl-S-C.sub.1-C.sub.6-alkyl, a 5- to 10-membered
heteroaryl-S(.dbd.O)--C.sub.1-C.sub.6-alkyl, a 5- to 10-membered
heteroaryl-S(.dbd.O).sub.2--C.sub.1-C.sub.6-alkyl and a 5- to
10-membered heteroaryl-C.sub.1-C.sub.6-alkyl, wherein any aryl and
heteroaryl may be optionally substituted with one or more
substituents selected from the group consisting of OH, CN, halo,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0019] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, a 5- to 10-membered
heteroaryl-C.sub.1-C.sub.6-alkyl, and C.sub.3-C.sub.6
cycloalkyl-C.sub.1-C.sub.6-alkyl, wherein any cycloalkyl, aryl and
heteroaryl, may be optionally substituted with one or more
substituents selected from the group consisting of OH, CN, halo,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.6 alkoxy;
[0020] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9;
--NR.sub.8R.sub.9; --O--NR.sub.8R.sub.9; --S(.dbd.O).sub.2OH;
--S(.dbd.O).sub.2NR.sub.8R.sub.9;
--NR.sub.8--S(.dbd.O).sub.2--R.sub.9;
--C(.dbd.O)NR.sub.8--S(.dbd.O).sub.2--R.sub.9;
--C(.dbd.O)NR.sub.8--S(.dbd.O).sub.2--NR.sub.28R.sub.29;
--NR.sub.28--C(.dbd.O)NR.sub.8--S(.dbd.O).sub.2--R.sub.9;
--NR.sub.28--C(.dbd.O)NR.sub.8R.sub.9; --S(.dbd.O).sub.2--R.sub.9;
--S(.dbd.O)--R.sub.9; C.sub.6-C.sub.10 aryl, or a 5-membered
nitrogen containing heteroaryl, wherein the aryl and heteroaryl may
be optionally substituted with one or more substituents selected
from the group consisting of OH, .dbd.O, CN, halo, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.4 alkoxy;
[0021] R.sub.5, at each occurrence, is independently selected from
H, C.sub.1-C.sub.6 alkyl and halo C.sub.1-C.sub.6 alkyl;
[0022] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl, halo C.sub.1-C.sub.6 alkyl and --C(.dbd.O)R.sub.7;
[0023] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy;
[0024] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo C.sub.1-C.sub.4 alkyl,
--C(.dbd.O)--C.sub.1-C.sub.4 alkyl, and halo-C.sub.1-C.sub.4
alkoxy;
[0025] R.sub.9 is independently selected from H, OH,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, C.sub.3-C.sub.6
cycloalkyl and C.sub.6-C.sub.10 aryl, wherein the alkyl, alkoxy,
cycloalkyl and aryl may be optionally substituted with one or more
substituents selected from the group consisting of OH, .dbd.O, CN,
halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0026] R.sub.28 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4-alkyl and
halo-C.sub.1-C.sub.4 alkoxy; and
[0027] R.sub.29 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4-alkyl and
halo-C.sub.1-C.sub.4 alkoxy.
[0028] In another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein A is a 8- to 11-membered bicyclic heterocyclyl,
wherein the bicyclic heterocyclyl contains at least two N
atoms.
[0029] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein A is a 8- to 10-membered bicyclic heterocyclyl,
wherein the bicyclic heterocyclyl contains at least two N
atoms.
[0030] In still yet another embodiment, the present invention
provides compounds, stereoisomers, tautomers, salts, solvates or
prodrugs thereof, wherein A is
##STR00003##
[0031] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein the compound is a compound of Formula Ia or Ib:
##STR00004##
[0032] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein A is a 6- to 7-membered monocyclic heterocyclyl, wherein
the heterocyclyl contains at least two N atoms.
[0033] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein X is independently selected from --C(.dbd.O)--NR.sub.5--;
--C(.dbd.O)--NR.sub.5--S(.dbd.O).sub.2--;
alkyl--NR.sub.5--C(.dbd.O)--; and a 5-membered nitrogen containing
heteroaryl.
[0034] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein X is independently selected from
--C(.dbd.O)--NR.sub.5--; alkyl-NR.sub.5--C(.dbd.O)--; and a
5-membered nitrogen containing heteroaryl.
[0035] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein X is independently selected from
--C(.dbd.O)--NR.sub.5--; and --C.sub.1-C.sub.6
alkyl--NR.sub.5--C(.dbd.O)--.
[0036] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein X is --C(.dbd.O)--NR.sub.5--.
[0037] In still yet another embodiment, the present invention
provides compounds, stereoisomers, tautomers, salts, solvates or
prodrugs thereof, wherein R.sub.2 is independently selected from
C.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.10
aryloxy-C.sub.1-C.sub.6-alkyl, C.sub.6-C.sub.10 C.sub.6-C.sub.10
aryl-S(.dbd.O).sub.2--C.sub.1-C.sub.6-alkyl and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4
alkoxy.
[0038] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein R.sub.2 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryloxy-C.sub.1-C.sub.6-alkyl,
C.sub.6-C.sub.10 aryl-S-C.sub.1-C.sub.6-alkyl and C.sub.6-C.sub.10
wherein any aryl may be optionally substituted with one or more
substituents selected from the group consisting of OH, CN, halo,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.4 alkoxy.
[0039] In another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein R.sub.2 is independently selected from
C.sub.1-C.sub.6 alkyl and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein the aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4
alkoxy.
[0040] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein R.sub.3 is independently selected from
C.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.10 aryl, C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, and a 5- to 10-membered
heteroaryl-C.sub.1-C.sub.6-alkyl, wherein any C.sub.6-C.sub.10 aryl
and heteroaryl, may be optionally substituted with one or more
substituents selected from the group consisting of OH, CN, halo,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.6 alkoxy
[0041] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein R.sub.3 is independently selected from C 1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, a 5-membered
heteroaryl-C.sub.1-C.sub.6-alkyl, and a 6-membered
heteroaryl-C.sub.1-C.sub.6-alkyl,wherein any aryl and heteroaryl,
may be optionally substituted with one or more substituents
selected from the group consisting of OH, CN, halo, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.6 alkoxy.
[0042] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein R.sub.3 is independently selected from
C.sub.1-C.sub.6 alkyl, C.sub.6-C.sub.10 aryl, and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.6
alkoxy.
[0043] In still yet another embodiment, the present invention
provides compounds, stereoisomers, tautomers, salts, solvates or
prodrugs thereof, wherein:
[0044] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9; C.sub.6-C.sub.10
aryl, or a 5-membered nitrogen containing heteroaryl, wherein the
aryl and heteroaryl may be optionally substituted with OH, .dbd.O,
CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0045] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4-alkyl and
halo-C.sub.1-C.sub.4 alkoxy; and
[0046] R.sub.9 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4-alkyl and
halo-C.sub.1-C.sub.4 alkoxy.
[0047] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein the 5-membered nitrogen containing heteroaryl in the
definition of R.sub.4 is selected from the group consisting of
##STR00005##
wherein Y is O, S, N or C and Z is O, S, or N(CH.sub.3).
[0048] In another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein:
[0049] A is a 8- to 11-membered bicyclic heterocyclyl, wherein the
bicyclic heterocyclyl contains at least two N atoms;
[0050] X is independently selected from --C(.dbd.O)--NR.sub.5--,
--C(.dbd.O)--NR.sub.5-S(.dbd.O).sub.2--, --C.sub.1-C.sub.6
alkyl-NR.sub.5--C(.dbd.O)--; and a 5-membered nitrogen containing
heteroaryl;
[0051] R.sub.1 is independently selected from --C.sub.1-C.sub.6
alkyl-NR.sub.5R.sub.6 and --NR.sub.5R.sub.6;
[0052] R.sub.2 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryloxy-C.sub.1-C.sub.6-alkyl,
C.sub.6-C.sub.10 aryl-S-C.sub.1-C.sub.6-alkyl,
aryl-S(.dbd.O)--C.sub.1-C.sub.6-alkyl, C.sub.6-C.sub.10
aryl-S(.dbd.O).sub.2-C.sub.1-C.sub.6-alkyl and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4
alkoxy;
[0053] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, C.sub.6-C.sub.10 and a 5- to
10-membered heteroaryl-C.sub.1-C.sub.6-alkyl, wherein any
C.sub.6-C.sub.10 aryl and heteroaryl, may be optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.6 alkoxy;
[0054] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9; C.sub.6-C.sub.10
aryl, or a 5-membered nitrogen containing heteroaryl, wherein the
aryl or heteroaryl may be optionally substituted with OH, .dbd.O,
CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0055] R.sub.5, at each occurrence, is independently selected from
H, C.sub.1-C.sub.6 alkyl and halo C.sub.1-C.sub.6 alkyl;
[0056] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl, halo C.sub.1-C.sub.6 alkyl and --C(.dbd.O)R.sub.7;.
[0057] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy;
[0058] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl;
and
[0059] R.sub.9 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl.
[0060] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein:
[0061] A is a 8- to 10-membered bicyclic heterocyclyl, wherein the
bicyclic heterocyclyl contains at least two N atoms;
[0062] X is independently selected from --C(.dbd.O)--NR.sub.5--;
--C.sub.1-C.sub.6 alkyl-NR.sub.5--C(.dbd.O)--; and a 5-membered
nitrogen containing heteroaryl;
[0063] R.sub.1 is independently selected from --C.sub.1-C.sub.6
alkyl-NR.sub.5R.sub.6 and --NR.sub.5R.sub.6;
[0064] R.sub.2 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryloxy-C.sub.1-C.sub.6-alkyl,
C.sub.6-C.sub.10 aryl-S--C.sub.1-C.sub.6-alkyl and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4
alkoxy;
[0065] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, C.sub.6-C.sub.10 and a 5-membered
heteroaryl-C.sub.1-C.sub.6-alkyl, wherein any C.sub.6-C.sub.10 aryl
and heteroaryl, may be optionally substituted with one or more
substituents selected from the group consisting of OH, CN, halo,
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.6 alkoxy;
[0066] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9; C.sub.6-C.sub.10
aryl, or a 5-membered nitrogen containing heteroaryl, wherein the
aryl or heteroaryl may be optionally substituted with OH, .dbd.O,
CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0067] R.sub.5, at each occurrence, is independently selected from
H, C.sub.1-C.sub.6 alkyl and halo C.sub.1-C.sub.6 alkyl;
[0068] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl, halo C.sub.1-C.sub.6 alkyl and --C(.dbd.O)R.sub.7;.
[0069] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy;
[0070] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl;
and
[0071] R.sub.9 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl.
[0072] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein:
[0073] A is a 8- to 10-membered bicyclic heterocyclyl, wherein the
bicyclic heterocyclyl contains at least two N atoms;
[0074] X is independently selected from --C(.dbd.O)--NR.sub.5--,
and --C.sub.1-C.sub.6 alkyl--NR.sub.5--C(.dbd.O)--,
[0075] R.sub.1 is independently selected from --C.sub.1-C.sub.6
alkyl-NR.sub.5R.sub.6 and --NR.sub.5R.sub.6;
[0076] R.sub.2 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryloxy-C.sub.1-C.sub.6-alkyl, and
aryl-C.sub.1-C.sub.6-alkyl, wherein any aryl may be optionally
substituted with one or more substituents selected from the group
consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
alkoxy, halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4
alkoxy;
[0077] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any C.sub.6-C.sub.10 aryl may
be optionally substituted with one or more substituents selected
from the group consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.6 alkoxy;
[0078] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, CN, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9; or
C.sub.6-C.sub.10 aryl, wherein the aryl may be optionally
substituted with OH, CN, halo, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.4 alkoxy;
[0079] R.sub.5, at each occurrence, is independently selected from
H, C.sub.1-C.sub.6 alkyl and halo C.sub.1-C.sub.6 alkyl;
[0080] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl, halo C.sub.1-C.sub.6 alkyl and --C(.dbd.O)R.sub.7;
[0081] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy;
[0082] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl;
and
[0083] R.sub.9 is independently selected from H, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, and halo-C.sub.1-C.sub.4-alkyl.
[0084] In yet another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein:
[0085] A is
##STR00006##
[0086] X is independently selected from --C(.dbd.O)--NR.sub.5--;
and --C.sub.1-C.sub.6 alkyl--NR.sub.5--C(.dbd.O)--;
[0087] R.sub.1 is independently selected from --C.sub.1-C.sub.6
alkyl-NR.sub.5R.sub.6 and --NR.sub.5R.sub.6;
[0088] R.sub.2 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.6-C.sub.10 aryl-C.sub.1-C.sub.6-alkyl, wherein the aryl
may be optionally substituted with one or more substituents
selected from the group consisting of OH, CN, halo, C.sub.1-C.sub.4
alkyl, C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.4 alkoxy;
[0089] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any C.sub.6-C.sub.10 aryl may
be optionally substituted with one or more substituents selected
from the group consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl,
C.sub.1-C.sub.4 alkoxy, halo-C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.6 alkoxy;
[0090] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, --C(.dbd.O)OH, --C(.dbd.O)NR.sub.8R.sub.9; or C.sub.6-C.sub.10
aryl, wherein the aryl may be optionally substituted with OH, CN,
halo, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
halo-C.sub.1-C.sub.4 alkyl or halo-C.sub.1-C.sub.4 alkoxy;
[0091] R.sub.5, at each occurrence, is independently selected from
H and C.sub.1-C.sub.6 alkyl;
[0092] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl and --C(.dbd.O)R.sub.7;
[0093] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy;
[0094] R.sub.8 is independently selected from H, C.sub.1-C.sub.4
alkyl and halo-C.sub.1-C.sub.4-alkyl; and
[0095] R.sub.9 is independently selected from H, C.sub.1-C.sub.4
alkyl and halo-C.sub.1-C.sub.4-alkyl.
[0096] In still yet another embodiment, the present invention
provides compounds, stereoisomers, tautomers, salts, solvates or
prodrugs thereof, wherein:
[0097] A is
##STR00007##
[0098] X is --C(.dbd.O)--NR.sub.5--;
[0099] R.sub.1 is --NR.sub.5R.sub.6;
[0100] R.sub.2 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.6-C.sub.10 aryl-C.sub.1-C.sub.6-alkyl, wherein the aryl
may be optionally substituted with one or more substituents
selected from the group consisting of OH, CN, halo, C.sub.1-C.sub.4
alkyl or halo-C.sub.1-C.sub.4 alkyl;
[0101] R.sub.3 is independently selected from C.sub.1-C.sub.6
alkyl, C.sub.6-C.sub.10 aryl, and C.sub.6-C.sub.10
aryl-C.sub.1-C.sub.6-alkyl, wherein any C.sub.6-C.sub.10 aryl may
be optionally substituted with one or more substituents selected
from the group consisting of OH, CN, halo, C.sub.1-C.sub.4 alkyl or
halo-C.sub.1-C.sub.4 alkyl;
[0102] R.sub.4 is C.sub.1-C.sub.6 alkyl, optionally substituted
with one or more substituents selected from the group consisting of
OH, --C(.dbd.O)OH, or C.sub.6-C.sub.10 aryl, wherein the aryl may
be optionally substituted with OH, CN, halo, C.sub.1-C.sub.4 alkyl
or halo-C.sub.1-C.sub.4 alkyl;
[0103] R.sub.5, at each occurrence, is independently selected from
H and C.sub.1-C.sub.6 alkyl;
[0104] R.sub.6 is independently selected from H, C.sub.1-C.sub.6
alkyl and --C(.dbd.O)R.sub.7;. and
[0105] R.sub.7 is independently selected from C.sub.1-C.sub.6 alkyl
and C.sub.1-C.sub.6 alkoxy.
[0106] In one embodiment, the present invention provides compounds,
stereoisomers, tautomers, salts, solvates or prodrugs thereof,
wherein the compound is selected from a compound set forth in the
examples.
[0107] In another embodiment, the present invention provides
compounds, stereoisomers, tautomers, salts, solvates or prodrugs
thereof, wherein the compound is selected from the compounds set
forth in Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39, 45
and 48.
[0108] The compounds, stereoisomers, tautomers, salts, solvates or
prodrugs of the invention have IC.sub.50 values in the TREX1
exonuclease assay (described hereinafter) of about 100 .mu.M or
less, preferably 50 .mu.M or less, and more preferably 25 .mu.M or
less, even more preferably 10 .mu.M or less. Activity data for
compounds, stereoisomers, tautomers, salts, solvates or prodrugs of
the present invention are presented in Table 5.
[0109] In some embodiments, the present invention provides a
pharmaceutical composition, which includes a pharmaceutically
acceptable carrier and a therapeutically effective amount of a
compound of Formula I, preferably, a compound selected from one of
the examples, more preferably, Examples 1, 2B, 3, 4, 14B, 15, 16,
17, 18, 36, 38, 39, 45 and 48, or stereoisomers, tautomers,
pharmaceutically acceptable salts, prodrug esters, or solvates
thereof, alone or in combination with another therapeutic
agent.
[0110] In some embodiments, the present invention provides a
pharmaceutical composition which further includes another
therapeutic agent(s). In a preferred embodiment, the present
invention provides a pharmaceutical composition, wherein the
additional therapeutic agent(s) are an anti-cancer agent, an
anti-viral compound, an antigen, an adjuvant, a lipid, a liposome,
a peptide, a cytotoxic agent, a chemotherapeutic agent, an
immunomodulatory cell line, a checkpoint inhibitor, a
biotherapeutic agent, an immunogenic agent, and cells transfected
with genes encoding immune stimulating cytokines or a combination
thereof. Preferably, the additional therapeutic agents are VEGF,
VEGFR, EGFR, Her2/neu, other growth factor receptors, CD20, CD40,
CD-40L, CTLA-4, OX-40, 4-1BB, ICOS, IL-2, IFNa.sub.2, GM-CSF, a
STING agonist, another TREX1 inhibitor, a CTLA-4 pathway
antagonist, a LAG-3 pathway antagonist, a PD-1 pathway antagonist,
a PD-L1 antibody, a vascular endothelial growth factor (VEGF)
receptor inhibitor, a topoisomerase II inhibitor, a smoothen
inhibitor, an alkylating agent, an anti-tumor antibiotic, an
anti-metabolite, a retinoid, Tim-3/gal9, CD73 inhibitors, adenosine
A2A+/-A2B antagonists and an anti-cancer vaccine.
[0111] In one embodiment, the present invention provides a
pharmaceutical composition which is utilized in combination with
radiation therapy.
[0112] In some embodiments, the present invention provides a method
for the treatment or prophylaxis of a disorder, disease, syndrome,
or condition, wherein said disease, syndrome, or condition is
affected by the inhibition of TREX1, which includes the step of
administering to a subject (for example, a human) in need of such
treatment or prophylaxis a therapeutically effective amount of at
least one of the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrug esters thereof
[0113] In some embodiments, the present invention provides methods
for the treatment of a disorder, disease, syndrome, or condition
affected by the inhibition of TREX1, which includes the steps of
administering to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45, and 48, or stereoisomers, tautomers, pharmaceutically
acceptable salts, prodrug esters, or solvates thereof, wherein the
disorder, disease, syndrome, or condition is selected cancer or a
viral infection.
[0114] In some embodiments, the present invention provides methods
for the treatment of a disease, syndrome, or condition affected by
the inhibition of TREX1, which includes the steps of administering
to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45 and 48, or stereoisomers, tautomers, pharmaceutically acceptable
salts, prodrug esters, or solvates thereof, wherein the disorder,
disease, syndrome, or condition is cancer.
[0115] In some embodiments, the present invention provides methods
for the treatment of cancer, which includes the steps of
administering to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45 and 48, or stereoisomers, tautomers, pharmaceutically acceptable
salts, prodrug esters, or solvates thereof, in combination with
radiation therapy.
[0116] In some embodiments, the present invention provides methods
for the treatment of a disorder, disease, syndrome, or condition
affected by the inhibition of TREX1, which includes the steps of
administering to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45 and 48, or stereoisomers, tautomers, pharmaceutically acceptable
salts, prodrug esters, or solvates thereof, wherein the disorder,
disease, syndrome, or condition is selected from the group
consisting of melanoma, colon cancer, breast cancer, prostate
cancer, lung cancer, bladder cancer and fibrosarcoma.
[0117] In some embodiments, the present invention provides methods
for the treatment of a disorder, disease, syndrome, or condition
affected by the inhibition of TREX1, which includes the steps of
administering to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45 and 48, or stereoisomers, tautomers, pharmaceutically acceptable
salts, prodrug esters, or solvates thereof, wherein the disorder,
disease, syndrome, or condition is a viral infection, preferably
HIV.
[0118] In some embodiments, the present invention provides methods
for the treatment of a disorder, disease, syndrome, or condition
affected by the inhibition of TREX1, which includes the steps of
administering to a patient (for example, a human) in need thereof a
therapeutically effective amount of a compound of Formula I,
preferably, a compound selected from one of the examples, more
preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17, 18, 36, 38, 39,
45 and 48, or stereoisomers, tautomers, pharmaceutically acceptable
salts, prodrug esters, or solvates thereof, wherein the disorder,
disease, syndrome, or condition is a HIV, melanoma, colon cancer,
breast cancer, prostate cancer, lung cancer, bladder cancer or
fibrosarcoma.
[0119] In yet another embodiment, the present invention provides
uses a compound of
[0120] Formula I, preferably, a compound selected from one of the
examples, more preferably, Examples 1, 2B, 3, 4, 14B, 15, 16, 17,
18, 36, 38, 39, 45 and 48, or stereoisomers, tautomers,
pharmaceutically acceptable salts, prodrug esters, or solvates
thereof, for the preparation of a medicament for treating a
disorder, disease, syndrome, or condition selected from the group
consisting of viral infection, melanoma, colon cancer, breast
cancer, prostate cancer, lung cancer, bladder cancer and
fibrosarcoma, in a subject in need thereof.
[0121] In still yet another embodiment, the present invention
provides uses a compound of Formula I, preferably, a compound
selected from one of the examples, more preferably, Examples 1, 2B,
3, 4, 14B, 15, 16, 17, 18, 36, 38, 39, 45 and 48, or stereoisomers,
tautomers, pharmaceutically acceptable salts, prodrug esters, or
solvates thereof, in a method for treating a disorder, disease,
syndrome, or condition selected from the group consisting of viral
infection, melanoma, colon cancer, breast cancer, prostate cancer,
lung cancer, bladder cancer and fibrosarcoma, in a subject in need
thereof.
Other Embodiments of the Invention
[0122] In some embodiments, the present invention provides a
process for making a compound of the present invention or a
stereoisomer, tautomer, pharmaceutically acceptable salt, solvate
or prodrug ester thereof
[0123] In some embodiments, the present invention provides an
intermediate for making a compound of the present invention or a
stereoisomer, tautomer, pharmaceutically acceptable salt, solvate
or prodrug ester thereof.
[0124] In some embodiments, the present invention provides a
compound of the present invention or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrug esters
thereof, for use in therapy for the treatment or prophylaxis of a
disorder, disease, syndrome, or condition affected by the
inhibition of TREX1.
[0125] In some embodiments, the present invention also provides the
use of a compound of the present invention or stereoisomers,
tautomers, pharmaceutically acceptable salts, solvates, or prodrug
esters thereof, for the manufacture of a medicament for the
treatment or prophylaxis of a disorder, disease, syndrome, or
condition affected by the inhibition of TREX1.
[0126] The present invention may be embodied in other specific
forms without departing from the spirit or essential attributes
thereof. This invention encompasses all combinations of preferred
aspects of the invention noted herein. It is understood that any
and all embodiments of the present invention may be taken in
conjunction with any other embodiment or embodiments to describe
additional embodiments. It is also to be understood that each
individual element of the embodiments is its own independent
embodiment. Furthermore, any element of an embodiment is meant to
be combined with any and all other elements from any embodiment to
describe an additional embodiment.
Chemistry
[0127] Compounds of this invention may have one or more asymmetric
centers. Unless otherwise indicated, all chiral (enantiomeric and
diastereomeric) and racemic forms of compounds of the present
invention are included in the present invention. Many geometric
isomers of olefins, C.dbd.N double bonds, and the like can also be
present in the compounds, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms. The present compounds can be isolated in optically active or
racemic forms. It is well known in the art how to prepare optically
active forms, such as by resolution of racemic forms or by
synthesis from optically active starting materials. All chiral,
(enantiomeric and diastereomeric) and racemic forms and all
geometric isomeric forms of a structure are intended, unless the
specific stereochemistry or isomer form is specifically indicated.
When no specific mention is made of the configuration (cis, trans
or R or S) of a compound (or of an asymmetric carbon), then any one
of the isomers or a mixture of more than one isomer is intended.
Preferably, diastereomers are resolved prior to any type of in
vitro or in vivo testing. The processes for preparation can use
racemates, enantiomers, or diastereomers as starting materials. All
processes used to prepare compounds of the present invention and
intermediates made therein are considered to be part of the present
invention. When enantiomeric or diastereomeric products are
prepared, they can be separated by conventional methods, for
example, by chromatography or fractional crystallization. Compounds
of the present invention, and salts thereof, may exist in multiple
tautomeric forms, in which hydrogen atoms are transposed to other
parts of the molecules and the chemical bonds between the atoms of
the molecules are consequently rearranged. It should be understood
that all tautomeric forms, insofar as they may exist, are included
within the invention.
[0128] As used herein, the term "alkyl" or "alkylene", alone or as
part of another group, is intended to include both branched and
straight-chain saturated aliphatic hydrocarbon groups having from 1
to 10 carbons or the specified number of carbon atoms. For example,
"C.sub.1-10 alkyl" (or alkylene), is intended to include C.sub.1,
C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.7, C.sub.8,
C.sub.9, and C.sub.10 alkyl groups. Additionally, for example,
"C.sub.1-C.sub.6 alkyl" denotes alkyl having 1 to 6 carbon atoms.
Alkyl groups can be unsubstituted or substituted with at least one
hydrogen being replaced by another chemical group. Example alkyl
groups include, but are not limited to, methyl (Me), ethyl (Et),
propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl,
isobutyl, t-butyl), and pentyl (e.g., n-pentyl, isopentyl,
neopentyl), as well as chain isomers thereof, and the like as well
as such groups which may optionally include 1 to 4 substituents
such as halo, for example F, Br, Cl, or I, or CF.sub.3, alkyl,
alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl,
arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl,
cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl,
heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl,
alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino,
arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl,
and/or alkylthio as well as (.dbd.O), OR.sub.18, SR.sub.18,
(.dbd.S), --NR.sub.18R.sub.19, --N(alkyl).sub.3.sup.+,
--NR.sub.18SO.sub.2, --NR.sub.18SO.sub.2R.sub.20,
--SO.sub.2R.sub.20, --SO.sub.2NR.sub.18R.sub.19,
--SO.sub.2NR.sub.18C(.dbd.O)R.sub.19, SO.sub.3H, --PO(OH).sub.2,
--C(.dbd.O)R.sub.18, --CO.sub.2R.sub.18,
--C(.dbd.O)NR.sub.18R.sub.19, --C(.dbd.O)(C.sub.1-C.sub.4
alkylene)NR.sub.18R.sub.19, --C(.dbd.O)NR.sub.18(SO.sub.2)R.sub.19,
--CO.sub.2(C.sub.1-C.sub.4 alkyl ene)NR.sub.18R.sub.19,
--NR.sub.18C(.dbd.O)R.sub.19, --NR.sub.18CO.sub.2R.sub.19,
--NR.sub.18(C.sub.1-C.sub.4 alkylene)CO.sub.2R.sub.19, .dbd.N--OH,
.dbd.N--O-alkyl, wherein R.sub.18 and R.sub.19 are the same or
different and are independently selected from hydrogen, alkyl,
alkenyl, CO.sub.2H, CO.sub.2(alkyl), C.sub.3-C.sub.7cycloalkyl,
phenyl, benzyl, phenylethyl, naphthyl, a 4- to 7-membered
heterocyclo, or a 5- to 6-membered heteroaryl, or when attached to
the same nitrogen atom may join to form a heterocyclo or
heteroaryl, and R.sub.20 is selected from same groups as R.sub.18
and R.sub.19 but is not hydrogen. Each group R.sub.18 and R.sub.19
when other than hydrogen, and each R.sub.20 group optionally has up
to three further substituents attached at any available carbon or
nitrogen atom of R.sub.18, R.sub.19, and/or R.sub.20, said
substituent(s) being the same or different and are independently
selected from the group consisting of (C.sub.1-C.sub.6)alkyl,
(C.sub.2-C.sub.6)alkenyl, hydroxy, halogen, cyano, nitro, CF.sub.3,
O(C.sub.1-C.sub.6 alkyl), OCF.sub.3, C(.dbd.O)H,
C(.dbd.O)(C.sub.1-C.sub.6 alkyl), CO.sub.2H,
CO.sub.2(C.sub.1-C.sub.6 alkyl), NHCO.sub.2(C.sub.1-C.sub.6 alkyl),
--S(C.sub.1-C.sub.6 alkyl), --NH.sub.2, NH(C.sub.1-C.sub.6 alkyl),
N(C.sub.1-C.sub.6 alkyl).sub.2, N(CH.sub.3).sub.3.sup.+,
SO.sub.2(C.sub.1-C.sub.6 alkyl), C(.dbd.O)(C.sub.1-C.sub.4
alkylene)NH.sub.2, C(.dbd.O)(C.sub.1-C.sub.4 alkylene)NH(alkyl),
C(.dbd.O)(C.sub.1-C.sub.4 alkylene)N(C.sub.1-C.sub.4 alkyl).sub.2,
C.sub.3-C.sub.7 cycloalkyl, phenyl, benzyl, phenylethyl, phenyloxy,
benzyloxy, naphthyl, a 4- to 7-membered heterocyclo, or a 5- to
6-membered heteroaryl. When a substituted alkyl is substituted with
an aryl, heterocyclo, cycloalkyl, or heteroaryl group, said ringed
systems are as defined below and thus may have zero, one, two, or
three substituents, also as defined below.
[0129] "Alkenyl" or "alkenylene", alone or as part of another
group, is intended to include hydrocarbon chains of either straight
or branched configuration and having one or more carbon-carbon
double bonds that may occur in any stable point along the chain.
For example, "C.sub.2-6 alkenyl" (or alkenylene), is intended to
include C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkenyl
groups. Examples of alkenyl include, but are not limited to,
ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl,
3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl,
2-methyl-2-propenyl, and 4-methyl-3-pentenyl, and which may be
optionally substituted with 1 to 4 substituents, namely, halogen,
haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl,
cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl,
alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol,
and/or alkylthio.
[0130] "Alkynyl" or "alkynylene", alone or as part of another
group, is intended to include hydrocarbon chains of either straight
or branched configuration and having one or more carbon-carbon
triple bonds that may occur in any stable point along the chain.
For example, "C.sub.2-6 alkynyl" (or alkynylene), is intended to
include C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkynyl
groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl,
and which may be optionally substituted with 1 to 4 substituents,
namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl,
arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl,
hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro,
cyano, thiol, and/or alkylthio.
[0131] The term "alkoxy" or "alkyloxy", alone or as part of another
group, refers to an --O-alkyl group, where alkyl is as defined
above. "C.sub.1-6 alkoxy" (or alkyloxy), is intended to include
C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, and C.sub.6 alkoxy
groups. Example alkoxy groups include, but are not limited to,
methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and
t-butoxy. Similarly, "alkylthio" or "thioalkoxy", alone or as part
of another group, represents an alkyl group or alkoxy group as
defined above with the indicated number of carbon atoms attached
through a sulphur bridge; for example methyl-S-- and ethyl-S--.
[0132] "Halo" or "halogen", alone or as part of another group,
includes fluoro, chloro, bromo, and iodo.
[0133] "Halo-C.sub.1-C.sub.6-alkyl" or "Haloalkyl" is intended to
include both branched and straight-chain saturated aliphatic
hydrocarbon groups having the specified number of carbon atoms,
substituted with 1 to 7 halogens, preferably 1 to 4 halogens,
preferably F and/or Cl. Examples of haloalkyl include, but are not
limited to, fluoromethyl, difluoromethyl, trifluoromethyl,
trichloromethyl, pentafluoroethyl, pentachloroethyl,
1,1-difluoroethyl, 1-fluoroethyl, 2,2,2-trifluoroethyl,
heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl
also include "fluoroalkyl" that is intended to include both
branched and straight-chain saturated aliphatic hydrocarbon groups
having the specified number of carbon atoms, substituted with 1 to
7 fluorine atoms, preferably 1 to 4 fluorine atoms.
[0134] "Halo-C.sub.1-C.sub.4-alkoxy" or "haloalkyloxy" represents a
haloalkyl group as defined above with the indicated number of
carbon atoms attached through an oxygen bridge. For example,
"C.sub.1-6 haloalkoxy", is intended to include C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, and C.sub.6 haloalkoxy groups. Examples
of haloalkoxy include, but are not limited to, trifluoromethoxy,
2,2,2-trifluoroethoxy, pentafluorothoxy, and the like. Similarly,
"haloalkylthio" or "thiohaloalkoxy" represents a haloalkyl group as
defined above with the indicated number of carbon atoms attached
through a sulphur bridge; for example trifluoromethyl-S-, and
pentafluoroethyl-S--.
[0135] Unless otherwise indicated, the term "cycloalkyl" as
employed herein alone or as part of another group includes
saturated or partially unsaturated (containing 1 or 2 double bonds)
cyclic hydrocarbon groups containing 1 to 3 rings, including
monocyclic alkyl, bicyclic alkyl (or bicycloalkyl), and tricyclic
alkyl, containing a total of 3 to 10 carbons forming the ring
(C.sub.3-C.sub.10 cycloalkyl), and which may be fused to 1 or 2
aromatic rings as described for aryl, which includes cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclodecyl, cyclododecyl, cyclohexenyl, cyclobutenyl,
norbornyl,
##STR00008##
any of which groups may be optionally substituted with 1 to 4
substituents such as halogen, alkyl, alkoxy, hydroxy, aryl,
aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo,
acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or
alkylthio, and/or any of the substituents for alkyl, as well as
such groups including 2 free bonds and thus are linking groups.
[0136] "Aryl" groups refer to monocyclic or polycyclic aromatic
hydrocarbons, including, for example, phenyl, naphthyl, and
phenanthranyl. Aryl moieties are well known and described, for
example, in Lewis, R. J., ed., Hawley's Condensed Chemical
Dictionary, 13th Edition, John Wiley & Sons, Inc., New York
(1997). "C.sub.6-10 aryl" includes phenyl and naphthyl. Unless
otherwise specified, "aryl", "C.sub.6-10 aryl" or "aromatic
residue" may be unsubstituted or substituted with 1 to 3 groups
selected from OH, OC.sub.1-C.sub.3 alkoxy, Cl, F, Br, I, CN,
NO.sub.2, NH.sub.2, N(CH.sub.3)H, N(CH.sub.3).sub.2, CF.sub.3,
OCF.sub.3, OCHF.sub.2, C(.dbd.O)CH.sub.3, SCH.sub.3,
S(.dbd.O)CH.sub.3, S(.dbd.O).sub.2CH.sub.3, C.sub.1-C.sub.3 alkyl,
CO.sub.2H, and CO.sub.2CH.sub.3.
[0137] As used herein, the term "heterocycle," "heterocyclo",
"heterocyclyl" or "heterocyclic" group is intended to mean a stable
4- to 14-membered monocyclic, bicyclic or tricyclic heterocyclic
ring which is saturated or partially unsaturated and which consists
of carbon atoms and 1, 2, 3, or 4 heteroatoms independently
selected from the group consisting of N, NH, O and S and including
any bicyclic group in which any of the above-defined heterocyclic
rings is fused to a benzene ring. The nitrogen and sulfur
heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and
S(O).sub.p, wherein p is 0, 1 or 2). The nitrogen atom may be
substituted or unsubstituted (i.e., N or NR wherein R is H or
another sub stituent, if defined). The heterocyclic ring may be
attached to its pendant group at any heteroatom or carbon atom that
results in a stable structure. The heterocyclic rings described
herein may optionally be substituted on carbon or on a nitrogen
atom if the resulting compound is stable, with 1 to 3 groups
selected from OH, OC.sub.1-C.sub.3 alkoxy, Cl, F, Br, I, CN,
NO.sub.2, NH.sub.2, N(CH.sub.3)H, N(CH.sub.3).sub.2, CF.sub.3,
OCF.sub.3, OCHF.sub.2, .dbd.O, C(.dbd.O)CH.sub.3, SCH.sub.3,
S(.dbd.O)CH.sub.3, S(.dbd.O).sub.2CH.sub.3, C.sub.1-C.sub.3 alkyl,
CO.sub.2H and CO.sub.2CH.sub.3. A nitrogen in the heterocycle may
optionally be quaternized. It is preferred that when the total
number of S and O atoms in the heterocycle exceeds 1, then these
heteroatoms are not adjacent to one another. It is preferred that
the total number of S and O atoms in the heterocycle is not more
than 1. Spiro and bridged rings are also included in the definition
of heterocycle. A bridged ring occurs when one or more atoms (i.e.,
C, O, N, or S) link two non-adjacent carbon or nitrogen atoms.
Examples of bridged rings include, but are not limited to, one
carbon atom, two carbon atoms, one nitrogen atom, two nitrogen
atoms, and a carbon-nitrogen group. It is noted that a bridge
always converts a monocyclic ring into a tricyclic ring. When a
ring is bridged, the substituents recited for the ring may also be
present on the bridge. When the term "heterocycle" or
"heterocyclyl" is used, it is not intended to include
heteroaryl.
[0138] Exemplary monocyclic heterocyclic groups include azetidinyl,
pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl,
thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidyl,
piperazinyl, 2-oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodinyl,
2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl,
morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide,
thiamorpholinyl sulfone, 1,3-dioxolane, and
tetrahydro-1,1-dioxothienyl, and the like.
[0139] Exemplary bicyclic heterocyclo groups include
quinuclidinyl.
[0140] Preferred heterocyclo groups include:
##STR00009##
which optionally may be substituted.
[0141] As used herein, the term "aromatic heterocyclic group" or
"heteroaryl" is intended to mean stable monocyclic and polycyclic
aromatic hydrocarbons that include at least one heteroatom ring
member such as sulfur, oxygen, or nitrogen. Heteroaryl groups
include, without limitation, pyridyl, pyrimidinyl, pyrazinyl,
pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl,
imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl,
benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl,
tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl,
carbazolyl, ben4zimidazolyl, indolinyl, benzodioxolanyl, and
benzodioxane. Heteroaryl groups are unsubstituted or substituted
with 1 to 3 groups selected from OH, OC.sub.1-C.sub.3 alkoxy, Cl,
F, Br, I, CN, NO.sub.2, NH.sub.2, N(CH.sub.3)H, N(CH.sub.3).sub.2,
CF.sub.3, OCF.sub.3, OCHF.sub.2, .dbd.O, C(.dbd.O)CH.sub.3,
SCH.sub.3, S(.dbd.O)CH.sub.3, S(.dbd.O).sub.2CH.sub.3,
C.sub.1-C.sub.3 alkyl, CO.sub.2H and CO.sub.2CH.sub.3. The nitrogen
atom is substituted or unsubstituted (i.e., N or NR wherein R is H
or another substituent, if defined). The nitrogen and sulfur
heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and
S(O).sub.p, wherein p is 0, 1 or 2). Bridged rings are also
included in the definition of heteroaryl. A bridged ring occurs
when one or more atoms (i.e., C, O, N, or S) link two non-adjacent
carbon or nitrogen atoms. Examples of bridged rings include, but
are not limited to, one carbon atom, two carbon atoms, one nitrogen
atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted
that a bridge always converts a monocyclic ring into a tricyclic
ring. When a ring is bridged, the substituents recited for the ring
may also be present on the bridge.
[0142] Preferred heteroaryl groups include:
##STR00010##
and the like.
[0143] The designation "" or "-" or "--" attached to a ring or
other group refers to a free bond or linking group.
[0144] Throughout the specification, groups and substituents
thereof may be chosen by one skilled in the field to provide stable
moieties and compounds and compounds useful as
pharmaceutically-acceptable compounds and/or intermediate compounds
useful in making pharmaceutically-acceptable compounds.
[0145] As referred to herein, the term "substituted" means that at
least one hydrogen atom is replaced with a non-hydrogen group,
provided that normal valencies are maintained and that the
substitution results in a stable compound. When a substituent is
keto (i.e., .dbd.O), then 2 hydrogens on the atom are replaced.
Ring double bonds, as used herein, are double bonds that are formed
between two adjacent ring atoms (e.g., C.dbd.C, C.dbd.N, or
N.dbd.N).
[0146] In cases wherein there are nitrogen atoms (e.g., amines) on
compounds of the present invention, these may be converted to
N-oxides by treatment with an oxidizing agent (e.g., mCPBA and/or
hydrogen peroxides) to afford other compounds of this invention.
Thus, shown and claimed nitrogen atoms are considered to cover both
the shown nitrogen and its N-oxide (N.fwdarw.O) derivative. In
cases in which there are quaternary carbon atoms in compounds of
the present invention, these can be replaced by silicon atoms,
provided they do not form Si--N or Si--O bonds.
[0147] When any variable occurs more than one time in any
constituent or formula for a compound, its definition at each
occurrence is independent of its definition at every other
occurrence. Thus, for example, if a group is shown to be
substituted with 0 to 3 R.sup.10, then said group may optionally be
substituted with up to three R.sup.10 groups, and at each
occurrence R.sup.10 is selected independently from the definition
of R.sup.10. Also, combinations of sub stituents and/or variables
are permissible only if such combinations result in stable
compounds.
[0148] When a bond to a substituent is shown to cross a bond
connecting two atoms in a ring, then such substituent may be bonded
to any atom on the ring. When a substituent is listed without
indicating the atom in which such substituent is bonded to the rest
of the compound of a given formula, then such substituent may be
bonded via any atom in such substituent. Combinations of
substituents and/or variables are permissible only if such
combinations result in stable compounds.
[0149] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions, and/or dosage
forms that are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
and/or other problem or complication, commensurate with a
reasonable benefit/risk ratio.
[0150] As used herein, "pharmaceutically acceptable salts" refer to
derivatives of the disclosed compounds wherein the parent compound
is modified by making acid or base salts thereof. Examples of
pharmaceutically acceptable salts include, but are not limited to,
mineral or organic acid salts of basic groups such as amines; and
alkali or organic salts of acidic groups such as carboxylic acids.
The pharmaceutically acceptable salts include the conventional
non-toxic salts or the quaternary ammonium salts of the parent
compound formed, for example, from non-toxic inorganic or organic
acids. For example, such conventional non-toxic salts include those
derived from inorganic acids such as hydrochloric, hydrobromic,
sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared
from organic acids such as acetic, propionic, succinic, glycolic,
stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic,
hydroxym al ei c, phenyl acetic, glutamic, benzoic, salicylic,
sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,
methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the
like.
[0151] The pharmaceutically acceptable salts of the present
invention can be synthesized from the parent compound that contains
a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a
mixture of the two; generally, nonaqueous media like ether, ethyl
acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists
of suitable salts are found in Remington: lhe Science and Practice
of Pharmacy, 22.sup.nd Edition, Allen, L. V. Jr., Ed.;
Pharmaceutical Press, London, UK (2012), the disclosure of which is
hereby incorporated by reference.
[0152] In addition, compounds of formula I may have prodrug forms.
Any compound that will be converted in vivo to provide the
bioactive agent (i.e., a compound of formula I) is a prodrug within
the scope and spirit of the invention. Various forms of prodrugs
are well known in the art. For examples of such prodrug
derivatives, see:
[0153] a) Bundgaard, H., ed., Design of Prodrugs, Elsevier (1985),
and Widder, K. et al., eds., Methods in Enzymology, 112:309-396,
Academic Press (1985);
[0154] b) Bundgaard, H., Chapter 5, "Design and Application of
Prodrugs," A Textbook of Drug Design and Development, pp. 113-191,
Krosgaard-Larsen, P. et al., eds., Harwood Academic Publishers
(1991);
[0155] c) Bundgaard, H., Adv. Drug Dehv. Rev., 8:1-38 (1992);
[0156] d) Bundgaard, H. et al., J. Pharm. Sci., 77:285 (1988);
[0157] e) Kakeya, N. et al., Chem. Pharm. Bull., 32:692 (1984);
and
[0158] f) Rautio, J (Editor). Prodrugs and Targeted Delivery
(Methods and Principles in Medicinal Chemistry), Vol 47, Wiley-VCH,
2011.
[0159] Preparation of prodrugs is well known in the art and
described in, for example, King, F. D., ed., Medicinal Chemistry:
Principles and Practice, The Royal Society of Chemistry, Cambridge,
UK (2.sup.nd edition, reproduced, 2006); Testa, B. et al.,
Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry
and Enzymology, VCHA and Wiley-VCH, Zurich, Switzerland (2003);
Wermuth, C. G., ed., The Practice of Medicinal Chemistry, 3.sup.rd
edition, Academic Press, San Diego, Calif. (2008).
[0160] Isotopically labeled compounds of the present invention,
i.e., wherein one or more of the atoms described are replaced by an
isotope of that atom (e.g., .sup.12C replaced by .sup.13C or by
.sup.14C; and isotopes of hydrogen including tritium and
deuterium), are also provided herein. Such compounds have a variety
of potential uses, e.g., as standards and reagents in determining
the ability of a potential pharmaceutical compound to bind to
target proteins or receptors, or for imaging compounds of this
invention bound to biological receptors in vivo or in vitro.
[0161] Compounds of the present invention are, subsequent to their
preparation, preferably isolated and purified to obtain a
composition containing an amount by weight equal to or greater than
98%, preferably 99%, compound of the present invention
("substantially pure"), which is then used or formulated as
described herein. Such "substantially pure" compounds are also
contemplated herein as part of the present invention.
[0162] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0163] The term "solvate" means a physical association of a
compound of this invention with one or more solvent molecules,
whether organic or inorganic. This physical association includes
hydrogen bonding. In certain instances the solvate will be capable
of isolation, for example when one or more solvent molecules are
incorporated in the crystal lattice of the crystalline solid.
"Solvate" encompasses both solution-phase and isolable solvates.
Exemplary solvates include, but are not limited to, hydrates,
ethanolates, methanolates, and isopropanolates. Methods of
solvation are generally known in the art.
[0164] Abbreviations as used herein, are defined as follows:
AcOH=acetic acid; Ala=alanine; Atm=atmosphere; ACN=acetonitrile;
Boc=t-butoxycarbonyl; BOP-Cl=bis(2-oxo-3-oxazolidinyl)phosphinic
chloride; t-Bu=tert-butyl; Cbz=carboxybenzyl; d=day;
DCM=dichloromethane; DIEA=DIPEA=N,N-diisopropylethylamine;
DMSO=dimethylsulfoxide;
EDAC=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride;
EtOAc=ethyl acetate; FCC=flash column chromatography;
Fmoc=fluorenylmethyloxycarbonyl; Glu=glutamic acid; h=hour;
HOBt=1-hydroxybenzotriazole; HPLC=high pressure liquid
chromatography; LCMS=liquid chromatography--mass spectrometry;
Leu=leucine; min=minute; MeOH=methanol; MPLC=medium pressure liquid
chromatography; NMR=nuclear magnetic resonance; Pd/C=palladium on
carbon; PyBOP=benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate; sat.=saturated; Ser=serine; SiO.sub.2=silica
gel; TEA=trimethylamine; TFA=trifluoroacetic acid; Tyr=tyrosine;
and Z=Cbz=carboxybenzyl.
[0165] The compounds of the present invention can be prepared in a
number of ways known to one skilled in the art of organic
synthesis. The compounds of the present invention can be
synthesized using the methods described below, together with
synthetic methods known in the art of synthetic organic chemistry,
or by variations thereon as appreciated by those skilled in the
art. Preferred methods include, but are not limited to, those
described below. The reactions are performed in a solvent or
solvent mixture appropriate to the reagents and materials employed
and suitable for the transformations being effected. It will be
understood by those skilled in the art of organic synthesis that
the functionality present on the molecule should be consistent with
the transformations proposed. This will sometimes require a
judgment to modify the order of the synthetic steps or to select
one particular process scheme over another in order to obtain a
desired compound of the invention.
[0166] During the chemical syntheses, various protecting groups may
be employed and subsequently removed in order to generate the
compounds of the present invention. Exemplary protecting groups and
conditions for their removal are described in Greene's Protecting
Groups in Organic Synthesis P. G. M. Nuts, T. W. Greene, Fourth
Edition, Wiley, New York, 2006.
EXAMPLES
[0167] The following compounds of the invention have been prepared,
isolated and characterized using the methods disclosed herein. They
demonstrate a partial scope of the invention and are not meant to
be limiting of the scope of the invention.
LCMS Analysis Methods:
[0168] Compounds were analyzed on an Acquity Ultra Performance
Liquid
[0169] Chromatography system employing an Acquity UPLC BEH C18, 1.7
.mu.m, 2.1.times.50 mm column. Detection was via an Aquity Ultra
Performance LC PDA detector and an Acquity SQD single quadrupole
mass spectrometer using H.sub.2O+0.1% formic acid (A) and ACN+0.1%
formic acid (B) as eluents.
[0170] Method A--Gradient: 0-0.1 min--Isocratic--10% B; 0.1-1.3
min--Linear gradient 10%-90% B; 1.3-1.8 min--Isocratic 90% B;
1.8-1.9 min--Linear gradien--90%-10% B; 1.9-2.0 min--Isocratic--B.
Flow rate: 0.6 mL/min.
[0171] Method B--Gradient: 0-0.1 min--Isocratic--40% B; 0.1-1.3
min--Linear gradient--5%-95% B; 1.3-1.8 min--Isocratic--95% B;
1.8-1.9 min--Linear gradient--60%-40% B; 1.9-2.0
min--Isocratic--40% B. Flow rate: 0.6 mL/min.
[0172] Method C--Gradient: 0-0.1 min--Isocratic--40% B; 0.1-1.0
min--Linear gradient 40%-99% B; 1.0-1.8 min--Isocratic 99% B;
1.8-1.9 min--Linear gradient--99%-40% B; 1.9-2.0
min--Isocratic--40% B. Flow rate: 0.6 mL/min.
HPLC Analysis Method:
[0173] Compounds were analyzed on a Waters Alliance 2695
High-Performance Liquid Chromatography system employing a SunFire
C.sub.18, 5 .mu.m, 4.6.times.100 mm column. Detection was via a
Waters 996 PDA detector using H.sub.2O+0.1% trifluoroacetic acid
(A) and ACN+0.1% trifluoroacetic acid (B) as eluents.
[0174] Gradient: 0-7.0 min--Linear gradient 10%-100% B; 7.0-8.0
min--Isocratic 100% B; 8.0-8.3 min--Linear gradient--100%-10% B;
8.3-10.0 min--Isocratic--10% B. Flow rate: 1.5 mL/min.
NMR Spectroscopy:
[0175] .sup.1H NMR Spectroscopy was performed on a Bruker 400 MHz
Avance II FTNMR Spectrometer. All .sup.1H NMR chemical shifts are
reported in parts per million (ppm) and either referenced to the
residual C-H signal from the deuterated solvent indicated or to
tetramethylsilane.
Intermediate I.1
(R)-tert-butyl
4-amino-5-oxo-5-((4-(trifluoromethyl)benzyl)amino)pentanoate
Step 1: (R)-tert-butyl
4-(((benzyloxy)carbonyl)amino)-5-oxo-5-((4-(trifluoromethyl)benzyl)amino)-
pentanoate
##STR00011##
[0177] To a mixture of Z-D-Glu-(Ot-Bu)-OH (1.00 g, 2.96 mmol) and
4-trifluoromethylbenzyl amine (0.42 mL, 3.0 mmol) in DCM (10 mL)
was added EDAC (680 mg, 3.55 mmol) followed by HOBt-H.sub.2O (480
mg, 3.55 mmol). The resultant reaction mixture was stirred at
ambient temperature for 16 h. The mixture was then concentrated in
vacuo and the crude residue was taken up in EtOAc (100 mL). This
was washed successively with sat. NaHSO.sub.4 (aq) (1.times.50 mL),
sat. NaHCO.sub.3 (aq) (1.times.50 mL) and brine (1.times.50 mL).
The organic layer was then dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to provide 1.39 g (95%) of (R)-tert-butyl
4-(((benzyloxy)carbonyl)amino)-5-oxo-5-((4-(trifluoromethyl)benzypamino)p-
entanoate which was used in the next step without further
purification.
Step 2: (R)-tert-butyl
4-amino-5-oxo-5((4-(trifluoromethyl)benzyl)amino)pentanoate
(Intermediate I.1)
##STR00012##
[0179] A mixture of the crude product obtained in step 1 above
(1.39 g, 2.81 mmol) and 10% Pd/C (100 mg) in MeOH (20 mL) was
stirred vigorously under 1 atm of H.sub.2 (g) (balloon) for 2.5 h.
The mixture was then filtered through a pad of Celite rinsing with
DCM and the filtrate was concentrated in vacuo to provide 1.01 g
(100%) of Intermediate I.1. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 7.73 (br t, 1H, N--H), 7.59 (d, 2H), 7.40 (d, 2H), 4.51 (d,
2H), 3.46 (dd, 1H), 2.44-2.31 (m, 2H), 2.20-2.12 (m, 1H), 1.89-1.80
(m, 1H), 1.44 (s, 9H) ppm; LCMS (Method A): t.sub.R=0.94 min, m/z
361.3 (M+H).sup.+, 305.2 (M+H--C.sub.4H.sub.8).sup.+, 721.4
(2M+H).sup.+.
Intermediate 1.2
(R)-2-amino-N-(3,4-dichlorobenzyl)-4-methylpentanamide
Step 1: (R)-tert-butyl
(1-((3,4-dichlorobenzyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate
##STR00013##
[0181] Using the same general procedure as described in Step 1 for
the preparation of Intermediate I.1, 3,4-dichlorobenzyl amine (1.14
g, 6.49 mmol) was reacted with Boc-D-Leu-OH (1.50 g, 6.49 mmol) to
provide 1.94 g (77%) of (R)-tert-butyl
(1-((3,4-dichlorobenzypamino)-4-methyl-1-oxopentan-2-yl)carbamate
after purification by FCC (SiO.sub.2, elution with 40%
EtOAc/hexanes). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.37 (d,
1H), 7.34 (d, 1H), 7.09 (dd, 1H), 6.70 (br t, 1H), 4.86 (br d, 1H),
4.38 (m, 2H), 4.11 (m, 1H), 1.74-1.66 (m, 2H), 1.52-1.47 (m, 1H),
1.42 (s, 9H), 0.95 (d, 3H), 0.93 (d, 2H) ppm; LCMS (Method A):
t.sub.R=1.41 min, m/z 389.3/391.3 (M+H).sup.+.
Step 2: (R)-2-amino-N-(3,4-dichlorobenzyl)-4-methylpentanamide
(Intermediate I.2):
##STR00014##
[0183] To a mixture of the intermediate obtained in step 1 above
(1.94 g, 5.00 mmol) in
[0184] DCM (15 mL) was added dropwise TFA (15 mL). The reaction
mixture was stirred at ambient temperature for 2 h, then quenched
with 2M NaOH to bring the pH to 9 and extracted with DCM
(2.times.50 mL). The combined organic layers were washed with sat.
NaHCO.sub.3 (aq) (1.times.50 mL), brine (1.times.50 mL), dried
(Na.sub.2SO.sub.4) and then filtered to provide 1.30 g (90%) of
Intermediate I.2 after purification by FCC (SiO.sub.2, elution with
0-10% MeOH/DCM). .sup.1H NMR (400 MHz, CDCl.sub.3): 67 7.79 (br t,
1H, N--H), 7.39 (d, 1H), 7.36 (d, 1H), 7.12 (dd, 1H), 4.39 (d, 2H),
3.45 (dd, 1H), 1.80-1.69 (m, 2H), 1.42-1.31 (m, 1H), 0.97 (d, 3H),
0.94 (d, 3H) ppm; LCMS (Method A): t.sub.R=0.88 min, m/z
289.2/291.2 (M+H).sup.+.
Intermediate 1.3
(R)-2-amino-3-(tert-butoxy)-N-(3,4-dichlorobenzyl)propanamide
Step 1: (R)-(9H-fluoren-9-yl)methyl (3-(ter
t-butoxy)-1-((3,4-dichlorobenzyl)amino)-1-oxopropan-2-yl)carbamate
##STR00015##
[0186] Using the same general procedure as described in Step 1 for
the preparation of Intermediate I.1, 3,4-dichlorobenzyl amine (173
.mu.L, 1.30 mmol) was reacted with Fmoc-D-Ser(t-Bu)OH (0.50 g, 1.3
mmol) to provide 0.64 g (91%) of (R)-(9H-fluoren-9-yl)methyl
(3-(tert-butoxy)-1-((3,4-dichlorobenzyl)amino)-1-oxopropan-2-yl)carbamate
after purification by FCC (SiO.sub.2, elution with 0-100%
EtOAc/hexanes). .sup.1H NMR (400 MHz, d.sub.6 DMSO): .delta. 8.55
(t, 1H), 7.89 (d, 2H), 7.74 (br d, 2H), 7.54 (d, 1H), 7.50 (d, 1H),
7.45-7.40 (m, 3H), 7.31 (td, 2H), 7.26 (dd, 1H), 4.37-4.20 (m, 5H),
4.12 (m, 1H), 3.50 (m, 2H), 1.11 (s, 9H) ppm; LCMS (Method B):
t.sub.R=1.36 min, m/z 541.3/543.4 (M+H).sup.+.
Step 2:
(R)-2-amino-3-(tert-butoxy)-N-(3,4-dichlorobenzyl)propanamide
(Intermediate 1.3)
##STR00016##
[0188] To a solution of (R)-(9H-fluoren-9-yl)methyl
(3-(tert-butoxy)-1-((3,4-dichlorobenzyl)amino)-1-oxopropan-2-yl)carbamate
(0.64 g, 1.18 mmol) in DCM (12 mL) was added diethylamine (2.50 mL,
23.7 mmol) and the reaction mixture was then stirred at ambient
temperature for 4 h. This was then concentrated in vacuo and the
crude residue was purified by FCC (SiO.sub.2, elution with 0-10%
MeOH/DCM) to provide 0.38 g (99%) of Intermediate I.3. .sup.1H NMR
(400 MHz, d.sub.6-DMSO): .delta. 8.46 (br t, 1H, N--H), 7.55 (d,
1H), 7.49 (d, 1H), 7.26 (dd, 1H), 4.28 (m, 2H), 3.39 (m, 2H), 3.27
(t, 1H), 1.81 (br s, 2H, NH2), 1.11 (s, 9H) ppm; LCMS (Method A):
t.sub.R=0.92 min, m/z 319.3/321.3 (M+H).sup.+.
[0189] Following the methods described above for the preparation of
Intermediates I.1-I.3, and substituting the corresponding reagents,
the following intermediates were prepared as indicated in Table
1.
TABLE-US-00001 TABLE 1 Inter- LCMS t.sub.R (M + H).sup.+ mediate
Structure Reagents Method (min) observed 1.4 ##STR00017##
4-methylbenzyl amine and Boc-D-Leu-OH A 0.75 235.3 1.5 ##STR00018##
Benzylamine and Boc- D-Leu-OH A 0.70 221.3 1.6 ##STR00019##
N-methyl-4- trifluoromethyl- benzylamine and Boc- D-Leu-OH A 0.89
303.3 1.7 ##STR00020## 3 ,4-dichlorobenzyl amine and Fmoc-D-
Tyr(t-Bu)OH A 1.06 395.3/397.3 1.8 ##STR00021## 4-
(trifluoromethyl)benzyl amine and Boc-D-Ala- OH A 0.74 247.3 1.9
##STR00022## 4- (trifluoromethyl)benzyl amine and Boc-D-Leu- OH A
0.84 289.3 1.10 ##STR00023## Cyclohexylmethyl amine and Boc-D-Leu-
OH A 0.80 227.3 1.11 ##STR00024## 3,4-dichlorobenzyl amine and
Cbz-D-Glu- (Ot-Bu)-OH A 0.97 361.3/363.3 1.12 ##STR00025##
3,4-dichlorobenzyl amine and Cbz-D-Asp- (Or-Bu)-OH A 0.92
347.2/349.2 1.13 ##STR00026## 3,4 -dichlorobenzyl amine and Fmoc-D-
Glu-(Trt)-OH A 1.22 546.3/548.3
Intermediate II.1
5-phenylpent-1-en-3-one
Step 1: N-methoxy-N-methyl-3-phenylpropanamide
##STR00027##
[0191] To a solution of 3-phenylpropionic acid (1.00 g, 6.66 mmol)
in DCM (20 mL) was added PyBOP (3.47 g, 6.66 mmol) followed by TEA
(1.1 mL, 7.6 mmol). The resultant mixture was stirred at ambient
temperature for 30 min. This was then cooled to 0.degree. C. and
N,O-dimethylhydroxyl amine.HCl (0.72 g, 7.33 mmol) was added
followed by additional TEA (1.1 mL, 7.6 mmol). The reaction mixture
was warmed to room temperature and stirred for 16 h. This was then
concentrated in vacuo and the crude residue was purified by FCC
(SiO.sub.2, elution with 0-100% EtOAc/hexanes) to provide 1.21 g
(94%) of N-methoxy-N-methyl-3-phenylpropanamide. .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 7.32-7.18 (m, 5H), 3.61 (s, 3H), 3.18 (s,
3H), 2.97 (t, 2H), 2.75 (t, 2H) ppm; LCMS (Method A): t.sub.R=1.04
min, m/z 194.4 (M+H).sup.+.
Step 2: 5-phenylpent-1-en-3-one (Intermediate II.1)
##STR00028##
[0193] To a solution of the Weinreb amide obtained in step 1 above
(0.20 g, 1.04 mmol) in anhydrous Et2O (5 mL) at 0.degree. C. was
added vinyl magnesium bromide (1.0 M in THF, 1.25 mL, 1.25 mmol).
The reaction mixture was stirred at 0.degree. C. for 30 min then
allowed to warm to room temperature and was stirred an additional
2.5 h. The reaction mixture was then cooled to 0.degree. C. and
additional vinyl magnesium bromide (1.0 M in THF, 0.40 mL, 0.40
mmol) was added. The resultant mixture was warmed to room
temperature and stirred an additional 1 h. The reaction mixture was
then quenched with 2 N HCl (aq) and extracted with EtOAc
(3.times.). The combined organic extracts were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The crude
residue was then taken up in DCM and filtered through a 1 gram
cartridge of SiO.sub.2, eluting with additional DCM. The filtrate
was concentrated in vacuo to provide 0.13 g (78%) of Intermediate
II.1. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.31-7.19 (m, 5H),
6.37 (dd, 1H), 6.22 (dd, 1H), 5.84 (dd, 1H), 2.99-2.89 (m, 4H)
ppm.
[0194] Using the synthetic method outlined above for the
preparation of Intermediate II .1 the following intermediates were
made from the corresponding reagent as indicated in Table 2.
TABLE-US-00002 TABLE 2 Intermediate Structure Reagent `HNMR II.2
##STR00029## Phenylacetic acid (400 MHz, CDCl.sub.3): .delta.
7.36-7.21(m, 5H), 6.42 (dd, 1H), 6.32 (dd, 1H), 6.84 (dd, 1H), 3.89
(s, 2H) ppm II.3 ##STR00030## 4-Chloro-phenylpropionic acid (400
MHz, CDCl.sub.3): .delta. 7.25 (d, 2H), 7.13 (d, 2H), 6.35 (dd,
1H), 6.21 (dd, 1H), 5.84 (dd, 1H), 2.95-2.87 (m, 4H) ppm
Example 1
(2R)-2-((8R,9aS)-8-amino-1-oxo-5-phenethylhexahydro-1H-pyrrolo[1,2-a][1,4]-
diazepin-2(3H)-yl)-N-(3,4-dichlorobenzyl)-4-methylpentanamide.HCl
Step 1:
(R)-N-(3,4-dichlorobenzyl)-4-methyl-2-((3-oxo-5-phenylpentyl)amino-
)pentanamide (Compound 1-1)
##STR00031##
[0196] A mixture of Intermediate I.2 (218 mg, 0.755 mmol) and
Intermediate II.1 (121 mg, 0.755 mmol) in DCM (5 mL) was stirred at
ambient temperature for 16 h. The mixture was then concentrated in
vacuo and the crude residue purified by FCC (SiO.sub.2, elution
with 0-10% MeOH/DCM) to provide 297 mg (88%) of Compound 1-1 as a
clear oil. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.88 (br t,
1H, amide N--H), 7.40 (d, 1H), 7.38 (d, 1H), 7.29-7.25 (m partially
obscured by solvent peak, 2H), 7.21-7.43 (m, 4H), 4.40 (m, 2H),
3.10 (dd, 1H), 2.89 (app t, 2H), 2.81-2.67 (m, 4H), 2.53 (m, 2H),
1.71-1.24 (m, 4H including amine N--H), 0.95 (d, 3H), 0.93 (d, 3H)
ppm.
Step 2: (2S,4R)-(9H-fluoren-9-yl)methyl
4-((tert-butoxycarbonyl)amino)-2-(4R)-1-((3,4-dichlorobenzyl)amino)-4-met-
hyl-1-oxopentan-2-yl)(3-oxo-5-phenylpentyl)carbamoyl)pyrrolidine-1-carboxy-
late (Compound 1-2)
##STR00032##
[0198] To a solution of (2S,4R)- Boc-4-amino-Fmoc proline (330 mg,
0.729 mmol) in DCM (2 mL) was added DIPEA (0.35 mL, 2.0 mmol). This
mixture was then added via pipette to a reaction vial containing
Compound 1-1 (297 mg, 0.662 mmol). The vessel originally containing
the proline reagent and DIPEA mixture was rinsed with DCM (1 mL)
and this was also added via pipette to the reaction vial. BOP-Cl
(96 mg, 0.38 mmol) was then added and the resultant reaction
mixture was stirred at ambient temperature for 3 d. The reaction
mixture was quenched with sat. NaHCO.sub.3 (aq) and extracted with
DCM (3.times.). The combined organic extracts were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The crude
residue was purified by FCC (SiO.sub.2, elution with 0-50%
EtOAc/hexanes) to provide 449 mg (77%) of Compound 1-2 as an
off-white solid. LCMS (Method A): t.sub.R=1.83 min, m/z 883.6/885.6
(M.+-.H).sup.+.
Steps 3 and 4: tert-butyl
((8R,9aS)-2-((R)-1-((3,4-dichlorobenzyl)amino)-4-methyl-1-oxopentan-2-yl)-
-1-oxo-5-phenethyloctahydro-1H-pyrrolo[1,2-a][1,4]diazepin-8-yl)carbamate
(Compound 1-3)
##STR00033##
[0200] To a solution of Compound 1-2 (445 mg; 0.503 mmol) in DCM (5
mL) was added dimethylamine (1.00 mL, 10.1 mmol) and this was
stirred for 3 h at ambient temperature. This mixture was then
concentrated in vacuo and the crude residue was taken up in MeOH (5
mL) and to this was added AcOH (0.10 mL) followed by NaCNBH3 (1 M
in THF, 0.65 mL, 0.65 mmol). The reaction mixture was stirred for
45 min. The mixture was then quenched with sat. NaHCO.sub.3 (aq)
and extracted with DCM (3.times.). The combined organic extracts
were dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo.
The crude residue was purified by FCC (SiO.sub.2, elution with
0-50% EtOAc/hexanes) to provide 255 mg (78%) of Compound 1-3 as
white solid. Analysis by LCMS indicated Compound 1-3 to be a
mixture of two diastereomers in a ratio of 88:12. This mixture of
diastereomers was carried directly into the next step. LCMS (Method
A): t.sub.R=1.38 min (major diastereomer, 88%) and 1.45 min (minor
diastereomer, 12%), m/z 645.5/647.5 (M+H).sup.+.
Step 5: Example 1
##STR00034##
[0202] Compound 1-3 (255 mg, 0.395 mmol) was taken up in 3N HCl in
MeOH (2 mL) and stirred at 40.degree. C. in a tightly capped
reaction vial for 2 h. The reaction temperature was increased to
50.degree. C. and stirring was continued for 30 min. The reaction
mixture was then cooled, concentrated in vacuo and the crude
residue was purified directly by mass-directed, preparative reverse
phase HPLC (C.sub.18 column, elution with 5-95% ACN/H.sub.2O
containing 0.25% formic acid). The desired fractions containing
mainly the desired first eluting (major) diastereomer and a small
amount of second eluting (minor) diastereomer were combined and
partially concentrated in vacuo. To this was added 3N HCl
(.about.10 mL) and the volatiles were removed in vacuo. This
treatment with 3N HCl was repeated to ensure formation of the
hydrochloride salt. The mixture was then concentrated in vacuo and
the residue was taken up in H.sub.2O and a small amount of ACN was
added to provide a clear solution which was lyophilized to provide
96 mg (42%) of Example 1 as an off-white solid. Analysis by HPLC
indicated Example 1 to be a mixture of diastereomers in a ratio of
96:4. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.52 (d, 1H), 7.47
(d, 1H), 7.32-7.19 (m, 6H), 5.22 (dd, 1H), 5.04 (m, 1H), 4.35 (ABq,
2H), 4.15 (m, 1H), 3.96 (m, 1H), 3.85-3.62 (m, 3H), 3.37 (m, 1H),
3.20 (m, 1H), 2.77 (m, 1H), 2.59 (m, 1H), 2.38-2.26 (m, 2H), 2.16
(m, 1H), 1.98-1.66 (m, 4H), 1.50 (m, 1H), 0.98 (d, 3H), 0.92 (d,
3H) ppm; LCMS (Method A): t.sub.R=1.17 min, m/z 545.4/547.4
(M+H).sup.+; HPLC: t.sub.R=4.866min (96%, major diastereomer) and
5.207 min (4%, minor diastereomer).
Example 2
(4R)-4-((8R,9aS)-8-amino-1-oxo-5-phenethylhexahydro-1H-pyrrolo[1,2-a][1,4]-
diazepin-2(3H)-yl)-5-oxo-5-44-(trifluoromethyl)benzyl)amino)pentanoic
acid
Steps 1-4: (4R)-tert-butyl
4-((8R,9aS)-8-((tert-butoxycarbonyl)amino)-1-oxo-5-phenethylhexahydro-1H--
pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl)-5-oxo-5-((4-(trifluoromethyl)benzyl)-
amino)pentanoate (Compound 2-3)
##STR00035##
[0204] Compound 2-3 was prepared from Intermediate I.1 (254 mg,
0.705 mmol) and Intermediate II.1 (113 mg, 0.705 mmol) using the
same general procedures described for the preparation of Compound
1-3 in steps 1-4 in Example 1. After work up the crude product was
purified by FCC (SiO.sub.2, elution with 0-100% EtOAc/hexanes) to
provide 56 mg of a first eluting, minor diastereomer (Compound
2-3A) and 124 mg of a second eluting, major diasteromer (Compound
2-3B). The pure minor diastereomer 2-3A and pure major diastereomer
2-3B were carried independently into the next step. Data for
Compound 2-3A (minor diastereomer): LCMS (Method A): t.sub.R=1.41
min, m/z 717.6 (M+H).sup.+. Data for Compund 2-3B (major
diastereomer): .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.61 (d,
2H), 7.51 (d, 2H), 7.25 (m, 2H), 7.15 (m, 3H), 5.13 (dd, 1H), 4.46
(ABq, 2H), 4.00 (m, 1H), 3.71 (dd, 1H), 3.56 (dd, 1H), 3.46-3.40
(m, 2H), 2.81 (m, 1H), 2.63-2.53 (m, 2H), 2.42 (m, 1H), 2.29-2.13
(m, 5H), 1.96-1.82 (m, 3H), 1.71 (m, 1H), 1.55 (m partially
obscured by singlet, 1H), 1.44 (s superimposed on multiplet, 18H),
ppm; LCMS (Method A): t.sub.R=1.33 min, m/z 717.6 (M+H).sup.+.
Step 5A:
(4R)-4-((8R,9aS)-8-amino-1-oxo-5-phenethylhexahydro-1H-pyrrolo[1,-
2-a][1,4]diazepin-2(3H)-yl)-5-oxo-5-((4-(trifluoromethyl)benzyl)amino)pent-
anoic acid (Example 2A)
##STR00036##
[0206] A solution of Compound 2-3A (55 mg, 0.077 mmol) in formic
acid (2 mL) was heated to 40.degree. C. for 2 h. The reaction
mixture was then concentrated in vacuo and the crude residue was
taken up in 1:1 ACN/H.sub.2O (2 mL) and then purified directly by
mass-directed preparative reverse phase HPLC (C-18, elution with
5-95% ACN/H.sub.2O containing 0.25% formic acid). The desired
fractions containing purified product were combined, diluted with
H.sub.2O, and lyophilized to provide 36 mg (84%) of Example 2A as a
white solid. 41 NMR (400 MHz, CD.sub.3OD): .delta. 7.62 (d, 2H),
7.47 (d, 2H), 7.27-7.13 (m, 5H), 5.14 (dd, 1H), 4.46 (s, 2H),
3.81-3.73 (m, 2H), 3.67 (dd, 1H), 3.51 (dd, 1H), 3.34 (m partially
obscured by solvent peak, 1H), 2.78-2.57 (m, 5H), 2.42-2.27 (m,
4H), 2.07-1.88 (m, 3H), 1.82-1.71 (m, 2H), ppm; LCMS (Method A):
t.sub.R=1.00 min, m/z 561.5 (M+H).sup.+.
Step 5B:
(4R)-4-((8R,9aS)-8-amino-1-oxo-5-phenethylhexahydro-1H-pyrrolo
[1,2-a][1,4]diazepin-2(3H)-yl)-5-oxo-5 -((4-(trifluoromethyl)b
enzyl)amino)pentanoi c acid (Example 2B)
##STR00037##
[0208] A solution of Compound 2-3B (124 mg, 0.173 mmol) in formic
acid (2 mL) was heated to 40.degree. C. for 2 h. The reaction
mixture was then concentrated in vacuo and the crude residue was
taken up in 1:1 ACN/H.sub.2O (2 mL) and then purified directly by
mass-directed preparative reverse phase HPLC (C-18, elution with
5-95% ACN/H.sub.2O containing 0.25% formic acid). The desired
fractions containing purified product were combined, diluted with
H.sub.2O, and lyophilized to provide 74 mg (76%) of Example 2B as a
white solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.60 (d,
2H), 7.50 (d, 2H), 7.25 (m, 2H), 7.17-7.14 (m, 3H), 5.09 (m, 1H),
4.46 (ABq, 2H), 3.82 (dd, 1H), 3.67-3.52 (m, 4H), 2.97 (m, 1H),
2.68-2.60 (m, 2H), 2.50 (m, 1H), 2.40 (app t, 1H), 2.20-2.03 (m,
4H), 1.97-1.82 (m, 3H), 1.67-1.55 (m, 2H) ppm; LCMS (Method A):
t.sub.R=0.95 min, m/z 561.5 (M+H).sup.+.
Example 3
(2R)-2-((8R,9aS)-8-amino-1-oxo-5-phenethylhexahydro-1H-pyrrolo[1,2-a][1,4]-
diazepin-2(3H)-yl)-N-(3,4-dichlorobenzyl)-3-hydroxypropanamide
HCl
Steps 1-4: tert-butyl
((8R,9aS)-2-((R)-3-(tert-butoxy)-1-((3,4-dichlorobenzyl)amino)-1-oxopropa-
n-2-yl)-1-oxo-5-phenethyloctahydro-1H-pyrrolo[1,2-a][1,4]diazepin-8-yl)car-
bamate (Compound 3-3)
##STR00038##
[0210] Compound 3-3 was prepared from Intermediate 1.3 (99 mg, 0.31
mmol) and Intermediate II.1 (50 mg, 0.31 mmol) using the same
general procedures described for the preparation of Compound 1-3 in
steps 1-4 in Example 1. After work up the crude product was
purified by FCC (SiO.sub.2, elution with 0-100% EtOAc/hexanes) to
provide 17 mg (13%) of a first eluting, minor diastereomer
(Compound 3-3A) and 91 mg (70%) of a second eluting, major
diastereomer (Compound 3-3B). The pure major diastereomer 3-3B was
carried into the next step. Data for Compound 3-3A (minor
diastereomer): LCMS (Method A): t.sub.R=0.90 min, m/z 675.4/677.3
(M+H).sup.+. Data for Compound 3-3B (major diastereomer): .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 7.39-7.36 (m, 2H), 7.28 (m
partially obscured by solvent peak, 2H), 7.20-7.08 (m, 6H), 4.95
(app t, 1H), 4.49-4.29 (m, 3H), 4.09 (m, 1H), 3.82 (dd, 1H),
3.67-3.62 (m, 2H), 3.51-3.44 (m, 3H), 2.91-2.51 (m, 4H), 2.45 (m,
1H), 2.23 (m, 1H), 1.91-1.82 (m, 2H), 1.67 (m partially obscured by
H.sub.2O peak, 1H), 1.44 (s, 9H), 1.17 (s, 9H) ppm; LCMS (Method
A): t.sub.R=0.87 min, m/z 675.4/677.3 (M+H).sup.+.
Step 5: Example 3
##STR00039##
[0212] Compound 3-3B (85 mg, 0.13 mmol) was treated with 3N HCl in
MeOH (2 mL) and the resultant reaction mixture was heated to
85.degree. C. in a tightly capped reaction vial for 2 h. The
reaction mixture was then cooled and concentrated in vacuo. The
crude residue was taken up in DMSO (1.5 mL) and then was purified
directly by mass-directed preparative reverse phase HPLC (elution
with 5-95% ACN/H.sub.2O containing 0.25% formic acid). The desired
fractions were combined and partially concentrated in vacuo. To
this was added 3N HCl (.about.10 mL) and the volatiles were removed
in vacuo. This treatment with 3N HCl was repeated to ensure
formation of the hydrochloride salt. The mixture was then
concentrated in vacuo and the residue was taken up in H.sub.2O and
a small amount of ACN was added to provide a clear solution which
was lyophilized to provide 26 mg (38%) of Example 3 as a yellow
solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.53 (d, 1H),
7.46 (d, 1H), 7.32-7.19 (m, 6H), 5.07 (dd, 1H), 4.97 (m partially
obscured by H.sub.2O peak, 1H), 4.38 (ABq, 2H), 4.12 (m, 1H),
4.03-3.88 (m, 3H), 3.85-3.79 (m, 2H), 3.65 (m, 1H), 3.34 (m
partially obscured by solvent peak, 1H), 3.20 (m, 1H), 2.77 (m,
1H), 2.60 (m, 1H), 2.36-2.25 (m, 2H), 2.17 (m, 1H), 2.05 (m, 1H),
1.87 (m, 1H) ppm; LCMS (Method A): t.sub.R=0.97 min, m/z
519.4/521.4 (M+H).sup.+.
[0213] Following the methods described above for Examples 1-3, and
substituting the corresponding intermediates, the following
examples were prepared as indicated in Table 3. Unless indicated
otherwise, the Examples in Table 3 were prepared from the major
diastereomer obtained in step 4 (intramolecular reductive
amination) of the synthesis.
TABLE-US-00003 TABLE 3 Intermediates LCMS tR (M + H).sup.+ Example
Structure and reagents Method (min) observed 4 ##STR00040## I.7 and
II.1 A 1.08 595.5/597.4 5 ##STR00041## I.8 and II.1 A 1.00 503.5 6
##STR00042## I.9 and II.1 A 1.07 545.5 7 ##STR00043## I.6 and II.1
A 1.12 559.5 8 ##STR00044## I.5 and II.1 A 0.98 477.5 9
##STR00045## I.4 and II.1 A 1.00 491.5 10 ##STR00046## I.2 and II.2
A 1.14 531.5/533.5 11 ##STR00047## I.2 and II.3 A 1.27 579.5/581.4/
583.4 12 ##STR00048## I.10 and II.1 A 1.07 483.6 13 ##STR00049##
I.2 and 3-buten-2-one A 0.96 455.4/457.4 14A ##STR00050## I.11 and
II.1 A 1.08 561.4/563.4 14B ##STR00051## I.11 and II.1 A 0.94
561.3/563.3 15 ##STR00052## I.12 and II.1 A 1.02 547.3/549.3 16
##STR00053## I.13 and II.1 A 0.99 560.4/562.3 17 ##STR00054## I.11
and phenoxymethyl vinyl ketone A 0.96 563.5/565.5 18 ##STR00055##
I.2 and (phenylsulfanyl)methyl vinyl ketone A 1.15 563.5/565.5 19
##STR00056## I.2 and II.4 A 1.11 547.4/549.4
Example 20
(2R)-2-((8R,9aS)-8-acetamido-1-oxo-5-phenethylhexahydro-1H-pyrrolo[1,2-a][-
1,4]diazepin-2(3H)-yl)-N-(3,4-dichlorobenzyl)-4-methylpentanamide.HCl
##STR00057##
[0215] To a solution of Example 1 (20 mg, 0.037 mmol) in DCM (1 mL)
was added TEA (15 .mu.L, 0.11 mmol) followed by acetyl chloride (5
.mu.L, 0.07 mmol). The resultant solution was stirred at ambient
temperature for 1 h. The mixture was then concentrated in vacuo and
the crude residue was taken up in MeOH (.about.1 mL) and to this
was added a small scoop of K.sub.2CO.sub.3. The mixture was stirred
for 15 min then diluted with DCM and filtered to remove
K.sub.2CO.sub.3. The filtrate was concentrated in vacuo and the
crude residue was purified directly by mass-directed preparative
reverse phase HPLC (elution with 5-95% ACN/H.sub.2O containing
0.25% formic acid). The desired fractions were combined and
partially concentrated in vacuo and the concentrate was treated
with 3 N HCl/MeOH (.about.5 mL) and then partially concentrated
again. The remaining solution was then treated once more with 3 N
HCl/MeOH s above and partially concentrated to ensure formation of
the HCl salt. The concentrated mixture was diluted with H.sub.2O
and lyophilized to provide 14 mg (64%) of Example 20 as a fluffy
white solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.50-7.47
(m, 2H), 7.33-7.20 (m, 6H), 5.23 (dd, 1H), 4.34 (s superimposed on
multiplet, 2H), 4.34-4.29 (m partially obscured by singlet, 1H),
4.08 (dd, 1H), 3.92 (dd, 1H), 3.70 (dd, 1H), 3.52 (app t, 1H), 3.19
(m, 1H), 2.98 (m, 1H), 2.80 (m, 1H), 2.61 (m, 1H), 2.43 (dd, 1H),
2.20 (m, 2H), 2.05-1.95 (m partially obscured by singlet, 1H), 1.96
(s, 3H), 1.80 (m, 2H), 1.66 (m, 1H), 1.49 (m, 1H), 1.33-1.29 (m,
1H), 0.98 (s, 3H), 0.92 (s, 3H) ppm; LCMS (Method A): tx=1.18 min,
m/z 587.5/589.5 (M+H).sup.+.
Example 21
(2R)-N-(3,4-dichlorobenzyl)-2-((8R,9aS)-8-(dimethylamino)-1-oxo-5-phenethy-
lhexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl)-4-methylpentanamide.HC-
l
##STR00058##
[0217] A solution of Example 1 (20 mg, 0.037 mmol) in 37%
formaldehyde (aq) (1 mL) and formic acid (1 mL) was heated to
100.degree. C. in a tightly capped reaction vial for 7 h. This was
then cooled and the mixture was purified directly by mass-directed
preparative reverse phase HPLC (elution with 5-95% ACN/H.sub.2O
containing 0.25% formic acid). The desired fractions were combined
and partially concentrated in vacuo and the concentrate was treated
with 3 N HCl/MeOH (.about.5 mL) and then partially concentrated
again. The remaining solution was then treated once more with 3 N
HCl/MeOH as above and partially concentrated to ensure formation of
the HCl salt. The concentrated mixture was diluted with H.sub.2O
and lyophilized to provide 14 mg (67%) of Example 21. .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 7.53 (m, 1H), 7.48 (d, 1H),
7.32-7.18 (m, 6H), 5.22 (m, 1H), 5.06 (m, 1H), 4.35 (ABq
superimposed on multiplet, 2H), 4.28 (m, partially obscured by AB
quartet, 1H), 4.01 (m, 1H), 3.83-3.55 (m, 4H), 3.29 (m partially
obscured by solvent peak, 1H), 3.00 (s, 6H), 2.76 (m, 1H), 2.57 (m,
2H), 2.36-2.21 (m, 2H), 1.98-1.80 (m, 2H), 1.72 (app t, 2H), 1.50
(m, 1H), 0.97 (d, 3H), 0.92 (d, 3H) ppm; LCMS (Method A):
t.sub.R=1.15 min, m/z 573.5/575.5 (M+H).sup.+.
Example 22
(2R)-2-((7R,8aS)-7-amino-1-oxo-4-phenethylhexahydropyrrolo[1,2-a]pyrazin-2-
(1H)-yl)-N-(3,4-dichlorobenzyl)-4-methylpentanamide.HCl
Step 1:
(R)-N-(3,4-dichlorobenzyl)-4-methyl-2-((2-oxo-4-phenylbutyl)amino)-
pentanamide (Compound 22-1)
##STR00059##
[0219] To a solution of Intermediate 1.2 (67 mg, 0.23 mmol) in DCM
(1 mL) was added 1-bromo-4-phenylbutan-2-one (50 mg, 0.22 mmol)
followed by TEA (34 .mu.L, 0.24 mmol). The reaction mixture was
stirred at ambient temperature for 4 h. The mixture was then
diluted with DCM and washed with sat. NaHCO.sub.3 (aq) (2.times.).
The organic layer was dried (MgSO.sub.4), filtered and concentrated
in vacuo. The crude residue was purified by FCC (SiO.sub.2, elution
with 0-100% EtOAc/hexanes) to provide 25 mg (26%) of Compound 22-1
as a yellow semi-solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
7.55 (br t, 1H, amide N--H), 7.38 (d, 1H), 7.33 (d, 1H), 7.30-7.26
(m partially obscured by solvent peak, 2H), 7.22-7.14 (m, 3H), 7.08
(dd, 1H), 4.36 (m, 2H), 3.37 (ABq, 2H), 3.05 (dd, 1H), 2.91 (t,
2H), 2.67 (t, 2H), 1.81-1.41 (m partially obscured by H.sub.2O
peak, 4H), 0.95 (d, 3H), 0.92 (d, 3H) ppm; LCMS (Method A):
t.sub.R=1.14 min, m/z 435.4/437.4 (M+H).sup.+.
Steps 2-4: tert-butyl
((7R,8aS)-2-((R)-1-((3,4-dichlorobenzyl)amino)-4-methyl-1-oxopentan-2-yl)-
-1-oxo-4-phenethyloctahydropyrrolo[1,2-a]pyrazin-7-yl)carbamate
(Compound 22-3)
##STR00060##
[0221] Compound 22-3 was prepared from Compound 22-1 (92 mg, 0.21
mmol) using the same general procedures described for the
preparation of Compound 1-3 in steps 2-4 in Example 1. After work
up, the crude product was purified by FCC (SiO.sub.2, elution with
0-70% EtOAc/hexanes). Partial separation of the two diastereomers
was achieved providing two fractions; one containing 29 mg of
mainly the first eluting, major diastereomer (Compound 22-3A) and
the other containing 17 mg of mainly the second eluting, minor
diastereomer (Compound 22-3B). A small amount of the other
diastereomer was present in each of the two fractions. The fraction
containing mainly the minor diastereomer 22-3B was carried into the
next step. Data for Compound 22-3A (major diastereomer): LCMS
(Method C): t.sub.R=0.92 min, m/z 631.4/633.3 (M+H).sup.+. Data for
Compound 22-3B (minor diastereomer): LCMS (Method C): t.sub.R=0.99
min, m/z 631.4/633.3 (M+H).sup.+.
Step 5: Example 22
##STR00061##
[0223] Compound 22-3B (16 mg, 0.025 mmol) was taken up in 3N HCl in
MeOH (1 mL) and the resultant solution was stirred at 50.degree. C.
in a tightly capped reaction vial for 90 min. The reaction mixture
was then cooled, concentrated in vacuo and the crude residue was
purified directly by preparative reverse phase MPLC (C.sub.18
column, elution with 5-95% ACN/H.sub.2O). The desired fractions
were combined and partially concentrated in vacuo. To this was
added 3N HCl (.about.10 mL) and the volatiles were removed in
vacuo. This treatment with 3N HCl was repeated to ensure formation
of the hydrochloride salt. The mixture was then concentrated in
vacuo and the residue was taken up in H.sub.2O and a small amount
of ACN was added to provide a clear solution which was lyophilized
to provide 11 mg (79%) of Example 22 as a white solid. .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 7.47 (d, 1H), 7.43 (d, 1H),
7.32-7.27 (m, 4H), 7.23-7.20 (m, 2H), 5.17 (dd, 1H), 4.55 (m, 1H),
4.33 (ABq, 2H), 4.10-3.42 (m, 6H), 2.90-2.76 (m, 3H), 2.45 (m, 1H),
2.15 (m, 1H), 2.00 (m, 1H), 1.81 (m, 1H), 1.66 (m, 1H), 1.45 (m,
1H), 1.01 (d, 3H), 0.94 (d, 3H) ppm; LCMS (Method A): t.sub.R=1.13
min, m/z 531.5/533.5 (M+H).sup.+.
[0224] Additional examples as set forth in Table 4 below were
prepared in accordance with the present invention:
TABLE-US-00004 TABLE 4 ##STR00062## ##STR00063## ##STR00064##
##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074##
##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079##
##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084##
##STR00085## ##STR00086## ##STR00087##
Biology
[0225] It is desirable to find compounds with advantageous and
improved characteristics compared with known TREX1 inhibitors, in
one or more of the following categories that are given as examples,
and are not intended to be limiting: (a) pharmacokinetic
properties, including oral bioavailability, half-life, and
clearance; (b) pharmaceutical properties; (c) dosage requirements;
(d) factors that increase the concentration of active drug at the
receptor; (e) factors that decrease the liability for clinical
drug-drug interactions; (f) factors that decrease the potential for
adverse side-effects, including selectivity versus other biological
targets; and (g) factors that improve manufacturing costs or
feasibility. 1001221 The term "compound", as used herein, means a
chemical, be it naturally-occurring or artificially-derived.
Compounds may include, for example, peptides, polypeptides,
synthetic organic molecules, naturally occurring organic molecules,
nucleic acid molecules, peptide nucleic acid molecules, and
components and derivatives thereof
[0226] As used herein, the term "patient" encompasses all mammalian
species.
[0227] As used herein, the term "subject" refers to any human or
nonhuman organism that could potentially benefit from treatment
with a TREX1 inhibitor. Exemplary subjects include human beings of
any age with risk factors for a disorder, disease, syndrome, or
condition affected by the inhibition of TREX1, or patients that
have already experienced one episode of a disorder, disease,
syndrome, or condition affected by the inhibition of TREX1.
[0228] As used herein, "treating" or "treatment" cover the
treatment of a disease-state in a mammal, particularly in a human,
and include: (a) inhibiting the disease-state, i.e., arresting its
development; and/or (b) relieving the disease-state, i.e., causing
regression of the disease state.
[0229] As used herein, "prophylaxis" or "prevention" covers the
preventive treatment of a subclinical disease-state in a mammal,
particularly in a human, aimed at reducing the probability of the
occurrence of a clinical disease-state. Patients are selected for
preventative therapy based on factors that are known to increase
risk of suffering a clinical disease state compared to the general
population. "Prophylaxis" therapies can be divided into (a) primary
prevention and (b) secondary prevention. Primary prevention is
defined as treatment in a subject that has not yet presented with a
clinical disease state, whereas secondary prevention is defined as
preventing a second occurrence of the same or similar clinical
disease state.
[0230] As used herein, "risk reduction" covers therapies that lower
the incidence of development of a clinical disease state. As such,
primary and secondary prevention therapies are examples of risk
reduction.
[0231] "Therapeutically effective amount" is intended to include an
amount of a compound of the present invention that is effective
when administered alone or in combination to modulate TREX1 and/or
to prevent or treat the disorders listed herein. When applied to a
combination, the term refers to combined amounts of the active
ingredients that result in the preventive or therapeutic effect,
whether administered in combination, serially, or
simultaneously.
[0232] As TREX1 inhibitors, it is believed that the compounds of
Formula I, and the examples are useful in methods for treating or
preventing cancer, disease, a syndrome, a condition or a disorder
in a subject, including an animal, a mammal and a human in which
the cancer, disease, the syndrome, the condition or the disorder is
affected by the modulation, including inhibition, of the TREX1
protein. Such methods comprise, consist of and/or consist
essentially of administering to a subject, including an animal, a
mammal, and a human, in need of such treatment or prevention, a
therapeutically effective amount of a compound, salt or solvate of
Formula I.
[0233] In one embodiment, the present invention is directed to a
compound of Formula I, or a stereoisomer, a tautomer, a salt, a
solvate or a prodrug form thereof, for the use in the treatment of
cancer, and cancer diseases and conditions, or a viral infection.
Examples of cancer diseases and conditions for which compounds of
Formula I, or a stereoisomer, a tautomer, a salt, a solvate or a
prodrug form thereof, may have potentially beneficial antitumor
effects include, but are not limited to, cancers of the lung, bone,
pancreas, skin, head, neck, uterus, ovaries, stomach, colon,
breast, esophagus, small intestine, bowel, endocrine system,
thyroid gland, parathyroid gland, adrenal gland, urethra, prostate,
penis, testes, ureter, bladder, kidney or liver; rectal cancer;
cancer of the anal region; carcinomas of the fallopian tubes,
endometrium, cervix, vagina, vulva, renal pelvis, renal cell;
sarcoma of soft tissue; myxoma; rhabdomyoma; fibroma; lipoma;
teratoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma;
hemagioma; hepatoma; fibrosarcoma; chondrosarcoma; myeloma; chronic
or acute leukemia; lymphocytic lymphomas; primary CNS lymphoma;
neoplasms of the CNS; spinal axis tumors; squamous cell carcinomas;
synovial sarcoma; malignant pleural mesotheliomas; brain stem
glioma; pituitary adenoma; bronchial adenoma;
[0234] chondromatous hanlartoma; inesothelioma; Hodgkin's Disease
or a combination of one or more of the foregoing cancers. Suitably
the present invention relates to a method for treating or lessening
the severity of cancers selected from the group consisting of brain
(gliomas), glioblastomas, astrocytomas, glioblastoma multiforme,
Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease,
Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,
medulloblastoma, head and neck, kidney, liver, melanoma, ovarian,
pancreatic, adenocarcinoma, ductal madenocarcinoma, adenosquamous
carcinoma, acinar cell carcinoma, glucagonoma, insulinoma,
prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid,
lymphoblastic T cell leukemia, chronic myelogenous leukemia,
chronic lymphocytic leukemia, hairy-cell leukemia, acute
lymphoblastic leukemia, acute myelogenous leukemia, chronic
neutrophilic leukemia, acute lymphoblastic T cell leukemia,
plasmacytoma, Immunoblastic large cell leukemia, mantle cell
leukemia, multiple myeloma, megakaryoblastic leukemia, multiple
myeloma, acute megakaryocytic leukemia, pro myelocytic leukemia,
erythroleukemia, malignant lymphoma, hodgkins lymphoma,
non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's
lymphoma, follicular lymphoma, neuroblastoma, bladder cancer,
urothelial cancer, vulval cancer, cervical cancer, endometrial
cancer, renal cancer, mesothelioma, esophageal cancer, salivary
gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal
cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal
stromal tumor) and testicular cancer.
[0235] In another embodiment, the present invention is directed to
a compound of Formula I, or a stereoisomer, a tautomer, a salt, a
solvate or a prodrug form thereof, for use in the treatment of a
disorder affected by the inhibition of TREX1 selected from the
group consisting of melanoma, colon cancer, breast cancer, prostate
cancer, lung cancer, bladder cancer, fibrosarcoma, and HIV.
[0236] In another embodiment, the present invention is directed to
a compound of Formula I, or a stereoisomer, a tautomer, a salt, a
solvate or a prodrug form thereof, for use in the treatment of a
disorder affected by the inhibition of TREXI wherein the disorder
is bladder cancer.
[0237] The term "pharmaceutical composition," as used herein, means
any composition, which contains at least one therapeutically or
biologically active agent and is suitable for administration to the
patient. Any of these formulations can be prepared by well-known
and accepted methods of the art. See, for example, Gennaro, A. R.,
ed., Remington: The Science and Practice of Pharmacy, 20th Edition,
Mack Publishing Co., Easton, Pa. (2000).
[0238] The invention includes administering to a subject a
pharmaceutical composition that includes a compound that modulates
TREX1 (referred to herein as a "TREX1 inhibitor" or "therapeutic
compound").
[0239] The compounds of this disclosure can be administered in such
oral dosage forms as tablets, capsules (each of which includes
sustained release or timed release formulations), pills, powders,
granules, elixirs, tinctures, suspensions, syrups, and emulsions.
They may also be administered in intravenous (bolus or infusion),
intraperitoneal, intravesical, subcutaneous, or intramuscular form,
and all using dosage forms well known to those of ordinary skill in
the pharmaceutical arts. They can be administered alone, but
generally will be administered with a pharmaceutical carrier
selected on the basis of the chosen route of administration and
standard pharmaceutical practice.
[0240] The preferred dose of the TREX1 inhibitor is a biologically
active dose. A biologically active dose is a dose that will
modulate the TREX1 protein and have an appropriate effect.
Desirably, the dose includes a dose range from about 0.0005 mg to
about 3000 mg, or any particular amount or range therein, in
particular from about 0.0005 mg to about 1000 mg, or any particular
amount or range therein, or, more particularly, from about 0.0005
mg to about 250 mg, or any particular amount or range therein, of
active ingredient in a regimen of about 1 to about 4 times per day
for an average (70 kg) human; although, it is apparent to one
skilled in the art that the therapeutically effective amount for a
compound of Formula I will vary as will the diseases, syndromes,
conditions, and disorders being treated.
[0241] Compounds of this invention can be administered in
intranasal form via topical use of suitable intranasal vehicles, or
via transdermal routes, using transdermal skin patches. When
administered in the form of a transdermal delivery system, the
dosage administration will, of course, be continuous rather than
intermittent throughout the dosage regimen.
[0242] Compounds of this invention can be administered in
intravesical form via a solution that is run through a tube
(instilled through a catheter) into the particular organ, for
example, the bladder, to treat the cancer.
[0243] The compounds are typically administered in a mixture with
suitable pharmaceutical diluents, excipients, or carriers
(collectively referred to herein as pharmaceutical carriers)
suitably selected with respect to the intended form of
administration, that is, oral tablets, capsules, elixirs, syrups
and the like, and consistent with conventional pharmaceutical
practices.
[0244] For instance, for oral administration in the form of a
tablet or capsule, the active drug component can be combined with
an oral, non-toxic, pharmaceutically acceptable, inert carrier such
as lactose, starch, sucrose, glucose, methyl cellulose, magnesium
stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol
and the like; for oral administration in liquid form, the oral drug
components can be combined with any oral, non-toxic,
pharmaceutically acceptable inert carrier such as ethanol,
glycerol, water, and the like. Moreover, when desired or necessary,
suitable binders, lubricants, disintegrating agents, and coloring
agents can also be incorporated into the mixture. Suitable binders
include starch, gelatin, natural sugars such as glucose or
beta-lactose, corn sweeteners, natural and synthetic gums such as
acacia, tragacanth, or sodium alginate, carboxymethylcellulose,
polyethylene glycol, waxes, and the like. Lubricants used in these
dosage forms include sodium oleate, sodium stearate, magnesium
stearate, sodium benzoate, sodium acetate, sodium chloride, and the
like. Disintegrators include, without limitation, starch, methyl
cellulose, agar, bentonite, xanthan gum, and the like.
[0245] The compounds of the present invention can also be
administered in the form of liposome delivery systems, such as
small unilamellar vesicles, large unilamellar vesicles, and
multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, such as cholesterol, stearylamine, or
phosphatidylcholines.
[0246] Compounds of the present invention may also be coupled with
soluble polymers as targetable drug carriers. Such polymers can
include polyvinylpyrrolidone, pyran copolymer,
polyhydroxypropylmethacrylamide-phenol,
polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine
substituted with palmitoyl residues. Furthermore, the compounds of
the present invention may be coupled to a class of biodegradable
polymers useful in achieving controlled release of a drug, for
example, polylactic acid, polyglycolic acid, copolymers of
polylactic and polyglycolic acid, polyepsilon caprolactone,
polyhydroxy butyric acid, polyorthoesters, polyacetals,
polydihydropyrans, polycyanoacylates, and crosslinked or
amphipathic block copolymers of hydrogels.
[0247] Dosage forms (pharmaceutical compositions) suitable for
administration will ordinarily contain the active ingredient in an
amount of about 0.5-95% by weight based on the total weight of the
composition.
[0248] Gelatin capsules may contain the active ingredient and
powdered carriers, such as lactose, starch, cellulose derivatives,
magnesium stearate, stearic acid, and the like. Similar diluents
can be used to make compressed tablets. Both tablets and capsules
can be manufactured as sustained release products to provide for
continuous release of medication over a period of hours. Compressed
tablets can be sugar coated or film coated to mask any unpleasant
taste and protect the tablet from the atmosphere, or enteric coated
for selective disintegration in the gastrointestinal tract.
[0249] Liquid dosage forms for oral administration can contain
coloring and flavoring to increase patient acceptance.
[0250] In general, water, a suitable oil, saline, aqueous dextrose
(glucose), and related sugar solutions and glycols such as
propylene glycol or polyethylene glycols are suitable carriers for
parenteral solutions. Solutions for parenteral administration may
contain a water soluble salt of the active ingredient, suitable
stabilizing agents, and if necessary, buffer substances.
Antioxidizing agents such as sodium bisulfite, sodium sulfite, or
ascorbic acid, either alone or combined, are suitable stabilizing
agents. Also used are citric acid and its salts and sodium EDTA. In
addition, parenteral solutions can contain preservatives, such as
benzalkonium chloride, methyl- or propyl-paraben, and
chlorobutanol.
[0251] Suitable pharmaceutical carriers are described in
Remington's Pharmaceutical Sciences, Mack Publishing Company, a
standard reference text in this field.
[0252] Representative useful pharmaceutical dosage-forms for
administration of the compounds of this invention can be
illustrated as follows:
Capsules
[0253] A large number of unit capsules can be prepared by filling
standard two-piece hard gelatin capsules each with 100 milligrams
of powdered active ingredient, 150 milligrams of lactose, 50
milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules
[0254] A mixture of active ingredient in a digestible oil such as
soybean oil, cottonseed oil or olive oil may be prepared and
injected by means of a positive displacement pump into gelatin to
form soft gelatin capsules containing 100 milligrams of the active
ingredient. The capsules should be washed and dried.
Tablets
[0255] Tablets may be prepared by conventional procedures so that
the dosage unit is 100 milligrams of active ingredient, 0.2
milligrams of colloidal silicon dioxide, 5 milligrams of magnesium
stearate, 275 milligrams of microcrystalline cellulose, 11
milligrams of starch and 98.8 milligrams of lactose. Appropriate
coatings may be applied to increase palatability or delay
absorption.
Dispersion
[0256] A spray dried dispersion can be prepared for oral
administration by methods know to one skilled in the art.
Injectable
[0257] A parenteral composition suitable for administration by
injection may be prepared by stirring 1._5% by weight of active
ingredient in 10% by volume propylene glycol and water. The
solution should be made isotonic with sodium chloride and
sterilized.
Suspension
[0258] An aqueous suspension can be prepared for oral
administration so that each 5 mL contain 100 mg of finely divided
active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg
of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025
mL of vanillin.
[0259] Where two or more of the foregoing second therapeutic agents
are administered with the compound of Formula I, preferably, a
compound selected from one of the examples, generally the amount of
each component in a typical daily dosage and typical dosage form
may be reduced relative to the usual dosage of the agent when
administered alone, in view of the additive or synergistic effect
of the therapeutic agents when administered in combination.
[0260] Particularly when provided as a single dosage unit, the
potential exists for a chemical interaction between the combined
active ingredients. For this reason, when the compound of the
examples and a second therapeutic agent are combined in a single
dosage unit they are formulated such that although the active
ingredients are combined in a single dosage unit, the physical
contact between the active ingredients is minimized (that is,
reduced). For example, one active ingredient may be enteric coated.
By enteric coating one of the active ingredients, it is possible
not only to minimize the contact between the combined active
ingredients, but also, it is possible to control the release of one
of these components in the gastrointestinal tract such that one of
these components is not released in the stomach but rather is
released in the intestines. One of the active ingredients may also
be coated with a material which effects a sustained-release
throughout the gastrointestinal tract and also serves to minimize
physical contact between the combined active ingredients.
Furthermore, the sustained-released component can be additionally
enteric coated such that the release of this component occurs only
in the intestine. Still another approach would involve the
formulation of a combination product in which the one component is
coated with a sustained and/or enteric release polymer, and the
other component is also coated with a polymer such as a low
viscosity grade of hydroxypropyl methylcellulose (HPMC) or other
appropriate materials as known in the art, in order to further
separate the active components. The polymer coating serves to form
an additional barrier to interaction with the other component.
[0261] These as well as other ways of minimizing contact between
the components of combination products of the present invention,
whether administered in a single dosage form or administered in
separate forms but at the same time by the same manner, will be
readily apparent to those skilled in the art, once armed with the
present disclosure.
[0262] Additionally, certain compounds disclosed herein may be
useful as metabolites of other compounds. Therefore, in one
embodiment, compounds may be useful either as a substantially pure
compound, which may also then be incorporated into a pharmaceutical
composition, or may be useful as metabolite which is generated
after administration of the prodrug of that compound. In one
embodiment, a compound may be useful as a metabolite by being
useful for treating disorders as described herein.
[0263] The disclosed compounds of Formula I may be useful in
combination with one or more additional therapeutic agents. The
additional therapeutic agent may be, e.g., radiation therapy, a
chemotherapeutic, a biotherapeutic agent (including but not limited
to antibodies to VEGF, VEGFR, EGFR, Her2/neu, other growth factor
receptors, CD20, CD40, CD-40L, CTLA-4, OX-40, 4-1BB, and ICOS), an
immunogenic agent (for example, attenuated cancerous cells, tumor
antigens, antigen presenting cells such as dendritic cells pulsed
with tumor derived antigen or nucleic acids, immune stimulating
cytokines (for example, IL-2, IFNa.sub.2, GM-CSF), and cells
transfected with genes encoding immune stimulating cytokines such
as but not limited to GM-CSF).
[0264] The additional therapeutic agent(s) may be administered in a
single dosage form with at least one compound of the present
invention, or the additional therapeutic agent(s) may be
administered in separate dosage form(s) from the dosage form
containing the compound of the present invention.
[0265] The compound of the present invention disclosed herein may
be used in combination with one or more other therapeutic agents,
including but not limited to, other anti-cancer agents that are
used in the prevention, treatment, control, amelioration, or
reduction of risk of a particular disease or condition. In one
embodiment, a compound disclosed herein is combined with one or
more other anti-cancer agents for use in the prevention, treatment,
control amelioration, or reduction of risk of a particular disease
or condition for which the compounds disclosed herein are useful.
Such other therapeutic agents may be administered, by a route and
in an amount commonly used therefor, contemporaneously or
sequentially with a compound of the present disclosure.
[0266] The additional therapeutic agent(s) may be one or more
agents selected from the group consisting of radiation therapy, a
STING agonist, anti-viral compounds, antigens, adjuvants,
anti-cancer agents, another TREX1 inhibitor, CTLA-4, LAG-3, PD-1
pathway antagonists, PD-L1 antibodies, lipids, liposomes, peptides,
cytotoxic agents, chemotherapeutic agents, immunomodulatory cell
lines, checkpoint inhibitors, vascular endothelial growth factor
(VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen
inhibitors, alkylating agents, anti-tumor antibiotics,
anti-metabolites, retinoids, and immunomodulatory agents including
but not limited to anti-cancer vaccines. It will be understood the
descriptions of the above additional therapeutic agents may be
overlapping. It will also be understood that the treatment
combinations are subject to optimization, and it is understood that
the best combination to use of the TREX1 inhibitor, and one or more
additional therapeutic agents will be determined based on the
individual patient needs.
[0267] When the compound disclosed herein is used contemporaneously
with one or more other therapeutic agents, the compound may be
administered either simultaneously with, or before or after, one or
more other therapeutic agent(s).
[0268] The weight ratio of the compound of the present invention
may be varied and will depend upon the therapeutically effective
dose of each agent. Generally, a therapeutically effective dose of
each will be used. Combinations including at least one compound of
the present invention, and other therapeutic agents will generally
include a therapeutically effective dose of each active agent. In
such combinations, the compound of the present invention disclosed
herein and other therapeutic agents may be administered separately
or in conjunction. In addition, the administration of one element
may be prior to, concurrent with, or subsequent to the
administration of other agent(s).
[0269] In one embodiment, this disclosure provides at least one
compound of the present invention, and at least one other
therapeutic agent as a combined preparation for simultaneous,
separate or sequential use in therapy. In one embodiment, the
therapy is the treatment of a disorder affected by the inhibition
of TREX1, such as cancer.
[0270] The disclosure also provides the use of a compound of
Formula I for treating a disorder affected by inhibition of TREX1,
where the patient has previously (e.g., within 24 hours) been
treated with another therapeutic agent.
[0271] Anti-viral compounds that may be used in combination with
the compounds disclosed herein include hepatitis B virus (HBV)
inhibitors, hepatitis C virus (HCV) protease inhibitors, HCV
polymerase inhibitors, HCV NS4A inhibitors, HCV NSSA inhibitors,
HCV NSSb inhibitors, and human immunodeficiency virus (HIV)
inhibitors.
[0272] Antigens and adjuvants that may be used in combination with
the compounds disclosed herein include B7 costimulatory molecule,
interleukin-2, interferon-y, GM-CSF, CTLA-4 antagonists,
OX-40/0X-40 ligand, CD40/CD40 ligand, sargramostim, levamisol,
vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum,
Freund's complete or incomplete adjuvant, detoxified endotoxins,
mineral oils, surface active substances such as lipolecithin,
pluronic polyols, polyanions, peptides, and oil or hydrocarbon
emulsions. Adjuvants, such as aluminum hydroxide or aluminum
phosphate, can be added to increase the ability of the vaccine to
trigger, enhance, or prolong an immune response. Additional
materials, such as cytokines, chemokines, and bacterial nucleic
acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as
well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8,
TLR.sub.9, including lipoprotein, lipopolysaccharide (LPS),
monophosphoryllipid A, lipoteichoic acid, imiquimod, resiquimod,
and in addition retinoic acid-inducible gene I (RIG-I) agonists
such as poly I:C, used separately or in combination are also
potential adjuvants.
[0273] Examples of cytotoxic agents that may be used in combination
with the compounds disclosed herein include, but are not limited
to, arsenic trioxide, asparaginase, and Erwinia L-asparaginase.
[0274] Chemotherapeutic agents that may be used in combination with
the compounds disclosed herein include abiraterone acetate,
altretamine, anhydrovinblastine, auristatin, bexarotene, bi
calutami de,
2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene
sulfonamide, bleomycin,
N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-1-Lproline-t-butyl-
amide, cachectin, cemadotin, chlorambucil, cyclophosphamide,
3',4'-didehydro-4'deoxy-8'-norvin-caleukoblastine, docetaxol,
doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin,
cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC),
dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin
(adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide,
hydroxyurea and hydroxyurea and taxanes, ifosfamide, liarozole,
lonidamine, lomustine (CCNU), MDV3100, mechlorethamine (nitrogen
mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef,
streptozocin, mitomycin, methotrexate, taxanes, nilutamide,
nivolumab, onapristone, paclitaxel, pembrolizumab, prednimustine,
procarbazine, RPR.sub.109881, stramustine phosphate, tamoxifen,
tasonermin, taxol, tretinoin, vinblastine, vincristine, vindesine
sulfate, and vinflunine, and pharmaceutically acceptable salts
thereof
[0275] Examples of vascular endothelial growth factor (VEGF)
receptor inhibitors include, but are not limited to, bevacizumab,
Brivanib Alaninate, motesanib, pasireotide, and sorafenib.
[0276] Examples of topoisomerase II inhibitors, include but are not
limited to, etoposide and teniposide.
[0277] Examples of hypomethylating agents and alkylating agents,
include but are not limited to, 5-azacytidine, decitabine,
temozolomide, dactinomycin, melphalan, phenylalanine mustard,
altretamine, carmustine, bendamustine, busulfan, carboplatin,
lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine,
altretamine, ifosfamide, procarbazine, mechlorethamine,
streptozocin, thiotepa, and pharmaceutically acceptable salts
thereof.
[0278] Examples of anti-tumor antibiotics include, but are not
limited to, doxorubicin, bleomycin, daunorubicin, daunorubicin
liposomal, mitoxantrone, epirubicin, idarubicin, and mitomycin
C.
[0279] Examples of anti-metabolites include, but are not limited
to, claribine, 5-fluorouracil, 6-thioguanine, pemetrexed,
cytarabine, cytarabine liposomal, decitabine, hydroxyurea
fludarabine, floxuridine, cladribine, methotrexate, and
pentostatin.
[0280] Examples of retinoids include, but are not limited to,
alitretinoin, tretinoin, isotretinoin and bexarotene.
[0281] Examples of PD-1 antagonists include, but are not limited
to, nivolumab, pembrolizumab, pidilizumab, and AMP-224.
[0282] Examples of PD-L1 antibodies include, but are not limited
to, Atezolizumab, Avelumab, and Durvalumab.
[0283] An example of a CLT-4 antagonist is ipilimumab.
[0284] Examples of STING agonists include, but are not limited to,
those disclosed in International Published Patent Application Nos.
WO 2017/027645 A1, WO 2017/027646 A1 and WO 2018/118664 A1.
[0285] The activity of the TREX1 inhibitors of the present
invention can be measured in a variety of in vitro assays.
Exemplary assays are shown in the Examples below.
[0286] The TREX1 Exonuclease assay is an exemplary in vitro assay
for measuring the activity of the TREX1 inhibitors of the present
invention. In this assay, TREX1 exonuclease activity was evaluated
by measuring the increase in fluorescence resulting from
TREX1-catalyzed removal of a quencher from the 3' end of a
FAM-labeled DNA oligonucleotide (5'FAM-CCA CGA GAG CGT-BHQ1-3').
The assay was conducted using Wild Type (WT) human or murine TREX1
enzyme constructs corresponding to amino acids 55-297 of UniProt ID
Q9NSU2-1 (SEQ ID NO: 1), or amino acids 1-242 of UniProt ID
Q91XBO-1 (SEQ ID NO: 2), respectively. See, e.g., Example A.
[0287] Example B is a protein thermal shift assay used to assess
the binding of TREX1 inhibitors to TREX1 protein. In this assay,
TREX1 protein unfolding with increasing temperature was measured in
the presence and absence of TREX1 inhibitors by following the
increase in fluorescence of a thiol-reactive dye (e.g BODIPY
FL-cystine) as it reacts with exposed TREX1 cysteine residues. The
assay was conducted using human (SEQ ID NO: 1), or murine (SEQ ID
NO: 2) TREX1 protein constructs.
[0288] Example C is a cell-based assay for TREX1 inhibitors using
THP1 Dual.TM. cells (Invivogen), a human monocyte cell line that
has stable integration of an Interferon Stimulated Response Element
(ISRE) Lucia reporter gene. The Lucia gene encodes a secreted
luciferase reporter protein, under the control of an ISG54 minimal
promoter in conjunction with five IFN-stimulated response elements.
Activation of the cGAS-STING pathway in THP1 Dual.TM. cells leads
to enhanced luciferase secretion and increased luminescence.
[0289] Example D is a cell based assay that measures the increase
in the expression of interferon stimulated genes (ISG) by RT-qPCR
that are induced by TREX1 inhibitors when THP1 Dual.TM. cells are
transfected with double-stranded DNA. The double stranded DNA used
to transfect cells was VACV-70 (Invivogen), a 70 base pair
oligonucleotide containing viral DNA motifs (Unterholzner L. et
al., 2010. IFI16 is an innate immune sensor for intracellular DNA.
Nat Immunol. 11(11):997-1004). Activation of cGAS-STING pathway in
THP1 Dual.TM. cells increases the expression of ISGs.
Assays
[0290] While it is apparent that the embodiments of the application
herein disclosed are well suited to fulfill the objectives stated
above, it will be appreciated that numerous modifications and other
embodiments may be implemented by those skilled in the art, and it
is intended that the appended claims cover all such modifications
and embodiments that fall within the true spirit and scope of the
present application.
Example A
TREX1 Exonuclease Assay
[0291] For human TREX1, the nucleotide sequence of the gene
construct was codon optimized for expression in the bacterial host.
The sequence was incorporated into the pMAL-c5e vector (NEB)
downstream of a solubility-promoting MBP (maltose binding protein)
fusion partner. The fusion protein product was expressed in E. coli
strain BL21 (DE3) (Millipore) and purified in a series of
chromatographic steps. Initial steps were conducted using a dextrin
sepharose affinity column followed by a Q-sepharose ion exchange
column (both GE Healthcare). After the second column the MBP
partner was removed by incubation with enterokinase (NEB). Further
purification was carried out with the second application of a
Q-sepharose column followed by a Superdex 75 (GE Healthcare) size
exclusion column. Finally, a heparin sepharose column (GE
Healthcare) was applied to remove contaminating nucleotides.
Similar methods were used in the preparation of the murine TREX1
enzyme and are described in Example B set forth below.
[0292] To evaluate the effect of compounds on TREX1 activity, test
compounds were serially diluted (11-point, 3-fold) from 10 mM stock
solutions and delivered to 384-well low-volume assay plates in 80
nL DMSO using an acoustic dispenser. Next, 4 .mu.L of human TREX1
(0.5 nM), or murine TREX1 (1 nM), diluted in assay buffer (20 mM
Tris pH 7.5, 5 mM MgCl.sub.2, 100 .mu.g/mL BSA, 0.002% Triton
X-100, 2 mM DTT), was added to the assay plate. After incubating
for 30 minutes, 4 .mu.L of labeled DNA oligonucleotide (500 nM) in
assay buffer was added to initiate TREX1 exonuclease activity. The
reaction was allowed to proceed for 45 minutes at room temperature
prior to the addition of 4 .mu.L of 150 mM EDTA to halt TREX1
activity. Assay plates were equilibrated for an additional 30
minutes and read on an EnVision Plate Reader (Perkin Elmer) to
measure fluorescence emission at 535 nm following excitation at 485
nm. Fluorescence was plotted as a function of log molar compound
concentration and fit to a four-parameter dose-response equation to
determine compound IC.sub.50.
[0293] Compounds of the present invention were tested in the TREX1
Exonuclease assay described immediately above and the results shown
in Table 5 below were obtained.
TABLE-US-00005 TABLE 5 A: IC.sub.50 < 1.00 .mu.M; B: IC.sub.50 =
1.00 .mu.M-9.99 .mu.M; C: IC.sub.50 = 10.0 .mu.M-100 .mu.M; D:
IC.sub.50 > 100 .mu.M Example Human TREX1 IC.sub.50 (.mu.M)
Murine TREX1 IC.sub.50 (.mu.M) 1 A A .sup. 2A C C .sup. 2B A A 3 A
A 4 A A 5 A A 6 A A 7 B B 8 B C 9 B B 10 B B 11 A B 12 C C 13 C C
.sup. 14A C C .sup. 14B A A 15 A A 16 A A 17 A A 18 A A 19 A B 20 B
C 21 C D 22 C C 23 B C 24 C C 25 C C 26 A B 27 B C 28 B C 29 B C 30
B C 31 A B 32 B C 33 A B 34 A B 35 B B 36 A A 37 A B 38 A A 39 A A
40 A B 41 B C 42 B B 43 A B 44 A B 45 A A 46 A B 47 B C 48 A A
Example B
TREX1 Thermal Shift Binding Assay
[0294] The thermal shift assays used recombinant protein
corresponding to human (SEQ ID NO: 1) and murine (SEQ ID NO: 2)
TREX1. The protein encoding plasmid contained a N-terminal MBP
(maltose binding protein) tag followed by the TREX1 coding sequence
within the pMAL-c5E vector. The plasmid was transfected into a BL21
(DE3) E. coli expression strain. Protein was purified from the
bacterial lysate using an Amylose resin column. The MBP tag was
cleaved from the purified protein using recombinant enterokinase
(EMD Millipore #69066-3). The cleaved TREX1 protein was further
purified on a Q-Sepharose column followed by a heparin column.
[0295] Binding of compounds to both human and murine TREX1 were
measured by protein thermal shift assays. (Huynh K, Partch C L.
Current Protocols in Protein Science: Analysis of protein stability
and ligand interactions by thermal shift assay. Current protocols
in protein science/editorial hoard, John E Coligan . [et al].
2015;79:28.9.1-28.9.14. doi:10.1002/0471140864.ps2809s79.). Thermal
shift assays were conducted in sealed 96-well PCR plates containing
5 .mu.M TREX1 protein, 100 .mu.M compound, and 2 .mu.M BODIPY
FL-cystine (Sigma) in either 20 .mu.L assay buffer (20 mM Tris,
7.5, 5 mM MgCl.sub.2, 0.002% Triton X-100) or 20 .mu.L phosphate
buffered saline (PBS). Using a RT-qPCR machine (Mx3005P,
Stratagene) changes in fluorescence (excitation at 492 nm and
emission at 516 nm) were monitored as temperature was increased
from 25.degree. C. to 96.degree. C. at a rate of 1.degree. C. every
2 minutes. T.sub.m values were calculated from the first derivative
plot of fluorescence intensity versus temperature. The results
shown in Table 6 indicate the examples bind to human TREX1 and
murine TREX1. ND indicates assay was not done.
TABLE-US-00006 TABLE 6 A: .DELTA.T.sub.m > 8.degree. C.; B:
8.degree. C. .gtoreq. .DELTA.T.sub.m .gtoreq. 4.degree. C. Thermal
shift Thermal shift cleaved human cleaved mouse TREX1, TREX1,
(.DELTA.Tm.degree. C.) (.DELTA.Tm.degree. C.) VB Assay Assay number
Example number PBS buffer PBS buffer Example 1 A A B B Example 2B A
A B B Example 3 A A B B Example 4 A A B B Example 14B ND A A ND
Example C
HP1 Monocyte Assay
[0296] A cell-based assay was established using THP1 Dual.TM. cells
(Invivogen), a human monocyte cell line that has stable integration
of an Interferon Stimulated Response Element (ISRE) Lucia reporter
gene. The Lucia gene encodes a secreted luciferase reporter
protein, under the control of an ISG54 minimal promoter in
conjunction with five IFN-stimulated response elements. Activation
of the cGAS-STING pathway in these cells leads to enhanced
luciferase secretion. The assay was conducted in standard 384-well
white tissue culture plates. Cells (25,000 in 25 .mu.L RPMI 1640
containing 10% Heat-Inactivated FBS, 1.times. Glutagro, 10 mM
HEPES, 1 mM sodium pyruvate, 1.times. Pen/Strep, 100 .mu.g/mL
Normocin, 100 .mu.g/mL Zeocin, 10 .mu.g/mL Blasticidin) were added
to the plate followed by 25 .mu.L of compound in the same
media+0.2% DMSO. The assay was incubated for 48 hours at 37.degree.
C. in 5% CO.sub.2. An aliquot of 5 .mu.l was removed to combine
with 12.5 .mu.L of the luciferase detection reagent, QUANTI-Luc.TM.
Gold (Invivogen) in a white 384-well plate. The luminescent signal
was then read using an EnVision plate reader (Perkin Elmer). The
fold activation was calculated by dividing the signal in wells
containing test compound by the signal in the control wells without
compound (see Table 7).
TABLE-US-00007 TABLE 7 Fold activation @ Example compound 10 .mu.M
Example 14B 12 Example 15 2 Example 16 4 Example 36 7
Example D
RT-qPCR Assay
[0297] The RT-qPCR assay was used to assess the ability of TREX1
inhibitors to enhance the expression of interferon stimulated genes
(ISGs) in cells transfected with double-stranded DNA. The double
stranded DNA used to transfect cells was VACV-70 (Invivogen), a 70
base pair oligonucleotide containing viral DNA motifs (Unterholzner
L. et al., 2010. IF116 is an innate immune sensor for intracellular
DNA. Nat Immunol. 11(11):997-1004). Human THP1 Dual.TM. cells
(Invivogen), were treated with test compound in the presence or
absence of 1,200 ng/mL VACV-70, or with VACV-70 alone, for 24
hours. Cells were harvested by centrifugation and washed with
phosphate buffer saline. Total RNA was isolated using Qiagen RNeasy
mini kit. Genomic DNA was degraded using Thermo Scientific DNase 1
kit. Total RNA was quantified using a Nanodrop spectrophotometer.
Using equal amounts of RNA, cDNA was synthesized using Invitrogen
Superstrand III First Strand synthesis kit. Target and reference
gene expression levels were determined by RT-qPCR using TaqMan gene
expression assays and a Stratagene Mx3005P QPCR system (all
reagents were from TaqMan, Applied Biosystems). Data were analyzed
by the Comparative C.sub.T method. GAPDH was used for
normalization. Target genes that were analyzed included interferon
stimulated genes (INF-.beta., CXCL10, IFIT1, IFIT2, IFIT3, IFI44,
and IFI44L). The data are shown in Table 8.
TABLE-US-00008 TABLE 8 IFN-.beta. CXCL10 IFIT1 IFIT2 IFIT3 IFI44
IFI44L Unstimulated control 1 1 1 1 1 1 1 VACV70 alone 732 185 813
518 355 827 2076 (Example 14B) alone 7 2 19 44 25 54 65 (Example
14B) + VACV70 2725 729 3580 7928 2297 2929 5263 (Example 15) alone
5 1 10 32 20 20 20 (Example 15) + VACV70 3449 712 4373 9581 3348
3969 3348 (Example 16) alone 6 2 11 41 25 14 15 (Example 16) +
VACV70 3692 1941 3676 8218 2729 3618 2729 (Example 36) alone 3 2 8
26 16 20 16 (Example 36) + VACV70 3856 1827 4391 11285 3768 4344
3768
[0298] While it is apparent that the embodiments of the application
herein disclosed are well suited to fulfill the objectives stated
above, it will be appreciated that numerous modifications and other
embodiments may be implemented by those skilled in the art, and it
is intended that the appended claims cover all such modifications
and embodiments that fall within the true spirit and scope of the
present application.
Sequence CWU 1
1
21242PRTHomo sapiens 1Met Gly Ser Gln Ala Leu Pro Pro Gly Pro Met
Gln Thr Leu Ile Phe1 5 10 15Phe Asp Met Glu Ala Thr Gly Leu Pro Phe
Ser Gln Pro Lys Val Thr 20 25 30Glu Leu Cys Leu Leu Ala Val His Arg
Cys Ala Leu Glu Ser Pro Pro 35 40 45Thr Ser Gln Gly Pro Pro Pro Thr
Val Pro Pro Pro Pro Arg Val Val 50 55 60Asp Lys Leu Ser Leu Cys Val
Ala Pro Gly Lys Ala Cys Ser Pro Ala65 70 75 80Ala Ser Glu Ile Thr
Gly Leu Ser Thr Ala Val Leu Ala Ala His Gly 85 90 95Arg Gln Cys Phe
Asp Asp Asn Leu Ala Asn Leu Leu Leu Ala Phe Leu 100 105 110Arg Arg
Gln Pro Gln Pro Trp Cys Leu Val Ala His Asn Gly Asp Arg 115 120
125Tyr Asp Phe Pro Leu Leu Gln Ala Glu Leu Ala Met Leu Gly Leu Thr
130 135 140Ser Ala Leu Asp Gly Ala Phe Cys Val Asp Ser Ile Thr Ala
Leu Lys145 150 155 160Ala Leu Glu Arg Ala Ser Ser Pro Ser Glu His
Gly Pro Arg Lys Ser 165 170 175Tyr Ser Leu Gly Ser Ile Tyr Thr Arg
Leu Tyr Gly Gln Ser Pro Pro 180 185 190Asp Ser His Thr Ala Glu Gly
Asp Val Leu Ala Leu Leu Ser Ile Cys 195 200 205Gln Trp Arg Pro Gln
Ala Leu Leu Arg Trp Val Asp Ala His Ala Arg 210 215 220Pro Phe Gly
Thr Ile Arg Pro Met Tyr Gly Val Thr Ala Ser Ala Arg225 230 235
240Thr Lys2242PRTMus musculus 2Met Gly Ser Gln Thr Leu Pro His Gly
His Met Gln Thr Leu Ile Phe1 5 10 15Leu Asp Leu Glu Ala Thr Gly Leu
Pro Ser Ser Arg Pro Glu Val Thr 20 25 30Glu Leu Cys Leu Leu Ala Val
His Arg Arg Ala Leu Glu Asn Thr Ser 35 40 45Ile Ser Gln Gly His Pro
Pro Pro Val Pro Arg Pro Pro Arg Val Val 50 55 60Asp Lys Leu Ser Leu
Cys Ile Ala Pro Gly Lys Ala Cys Ser Pro Gly65 70 75 80Ala Ser Glu
Ile Thr Gly Leu Ser Lys Ala Glu Leu Glu Val Gln Gly 85 90 95Arg Gln
Arg Phe Asp Asp Asn Leu Ala Ile Leu Leu Arg Ala Phe Leu 100 105
110Gln Arg Gln Pro Gln Pro Cys Cys Leu Val Ala His Asn Gly Asp Arg
115 120 125Tyr Asp Phe Pro Leu Leu Gln Thr Glu Leu Ala Arg Leu Ser
Thr Pro 130 135 140Ser Pro Leu Asp Gly Thr Phe Cys Val Asp Ser Ile
Ala Ala Leu Lys145 150 155 160Ala Leu Glu Gln Ala Ser Ser Pro Ser
Gly Asn Gly Ser Arg Lys Ser 165 170 175Tyr Ser Leu Gly Ser Ile Tyr
Thr Arg Leu Tyr Trp Gln Ala Pro Thr 180 185 190Asp Ser His Thr Ala
Glu Gly Asp Val Leu Thr Leu Leu Ser Ile Cys 195 200 205Gln Trp Lys
Pro Gln Ala Leu Leu Gln Trp Val Asp Glu His Ala Arg 210 215 220Pro
Phe Ser Thr Val Lys Pro Met Tyr Gly Thr Pro Ala Thr Thr Gly225 230
235 240Thr Thr
* * * * *